{
  "name" : "dacemirror.sci-hub.se_journal-article_93b1e8ce70b251fd162d7f9163f0f2a0_fan2019.pdf",
  "metadata" : {
    "source" : "CRF",
    "title" : "Breaking the Depth Dependence by Nanotechnology- Enhanced X-Ray-Excited Deep Cancer Theranostics",
    "authors" : [ "Wenpei Fan", "Wei Tang", "Joseph Lau", "Zheyu Shen", "Jin Xie", "Jianlin Shi", "Xiaoyuan Chen" ],
    "emails" : [ "wei.tang4@nih.gov;", "shawn.chen@nih.gov" ],
    "sections" : [ {
      "heading" : null,
      "text" : "REVIEW\n1806381 (1 of 32) © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.advmat.de\nBreaking the Depth Dependence by NanotechnologyEnhanced X-Ray-Excited Deep Cancer Theranostics\nWenpei Fan, Wei Tang,* Joseph Lau, Zheyu Shen, Jin Xie, Jianlin Shi, and Xiaoyuan Chen*\nDr. W. Fan, Dr. W. Tang, Dr. J. Lau, Dr. Z. Shen, Prof. X. Chen Laboratory of Molecular Imaging and Nanomedicine National Institute of Biomedical Imaging and Bioengineering National Institutes of Health Bethesda, MD 20892, USA E-mail: wei.tang4@nih.gov; shawn.chen@nih.gov Prof. J. Xie Department of Chemistry University of Georgia Athens, GA 30602, USA Prof. J. Shi State Key Laboratory of High Performance Ceramics and Superfine Microstructures Shanghai Institute of Ceramics Chinese Academy of Sciences Shanghai 200050, P. R. China\nThe ORCID identification number(s) for the author(s) of this article can be found under https://doi.org/10.1002/adma.201806381.\nDOI: 10.1002/adma.201806381\ntreat cancer patients; however, it can cause severe systemic toxicity and immunesystem depression due to its nonspecific nature.[2–4] As a noninvasive therapeutic modality, radiotherapy (RT) with assistance from image guidance/positioning can be used to deliver X/γ-ray radiation to tumors.[5–8] This enables radiation oncologists to target malignant tissues for precise cancer therapy[9–11] while minimizing radiation dose delivered to surrounding normal tissues. However, RT efficacy can be attenuated by factors like salient hypoxia found in solid tumors.[12–15] Moreover, some cancer subtypes and cancer stem cells exhibit high resistance to X-ray radiation.[16] Consequently, the development of radiosensitizers that can sensitize hypoxic or radio-resistant tumors to X-ray radiation[17–20] has become an area of intense research.\nThe emerging radiosensitizers can be classified into three groups: gasotransmitters (e.g., O2, NO, H2S, etc.),[21–25] anti-\ncancer drugs (e.g., paclitaxel (PTX), docetaxel (Dtxl), topotecan (TPT), etc.),[26–28] and high-Z elements (e.g., Au, Ba, Bi, Pt, W, etc.).[29–35] The gasotransmitters can mimic the radiosensitizing effect of oxygen and downregulate hypoxia-inducible factor-1 alpha (HIF-1α) expression,[23] while anticancer drugs can induce cancer cells to enter the G2/M phase which is the most radiation-sensitive cell-cycle phase.[36] High-Z elements are known for scattering one X-ray beam into several beams to concentrate more radiation on tumors for aggravated radiation damage.[37,38] This radiation dose–amplification effect is based on the Compton scattering mechanism.[39] All of these radiosensitizers are usually loaded or engineered into nanocarriers for tumor-specific delivery or by passive tumor accumulation via the enhanced permeability and retention (EPR) effect.[40] Heretofore, a great number of nanomaterials have been synthesized to pave the way for high-performance radiosensitization for RT enhancement.[41–44]\nDespite the appreciable progress achieved in X-ray radiation sensitization/enhancement, RT as a monotherapy generally fails to eliminate the whole tumor as cancer cells can undergo DNA-repair and regrowth.[45,46] As such, current research is gradually shifting from RT monotherapy to X-rayexcited multimodal therapy. This means that two or more therapeutic modalities are simultaneously activated by X-ray to yield synchronous/synergistic anticancer effects.[47–49] For example, it has been shown that high-energy X-ray irradiation can trigger\nThe advancements in nanotechnology have created multifunctional nanomaterials aimed at enhancing diagnostic accuracy and treatment efficacy for cancer. However, the ability to target deep-seated tumors remains one of the most critical challenges for certain nanomedicine applications. To this end, X-ray-excited theranostic techniques provide a means of overcoming the limits of light penetration and tissue attenuation. Herein, a comprehensive overview of the recent advances in nanotechnology-enhanced X-ray-excited imaging and therapeutic methodologies is presented, with an emphasis on the design of multifunctional nanomaterials for contrast-enhanced computed tomography (CT) imaging, X-ray-excited optical luminescence (XEOL) imaging, and X-ray-excited multimodal synchronous/synergistic therapy. The latter is based on the concurrent use of radiotherapy with chemotherapy, gas therapy, photodynamic therapy, or immunotherapy. Moreover, the featured biomedical applications of X-ray-excited deep theranostics are discussed to highlight the advantages of X-ray in high-sensitivity detection and efficient elimination of malignant tumors. Finally, key issues and technical challenges associated with this deep theranostic technology are identified, with the intention of advancing its translation into the clinic.\nCancer Theranostics"
    }, {
      "heading" : "1. Introduction",
      "text" : "Cancer remains one of the deadliest diseases globally, despite the collective efforts of research scientists and clinicians. In the United States alone, it is predicted that there will be 1 735 350 incidences of cancer and 609 640 cancer deaths in the year 2018.[1] Chemotherapy is commonly administered to\nAdv. Mater. 2019, 1806381\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1806381 (2 of 32)\nthe decomposition of diselenide-containing polymeric nanoparticles for drug release by breaking down the low-energy SeSe bond,[50] leading to combinational RT and chemotherapy. X-ray can be transformed into ultraviolet–visible (UV–vis) light by nanoscintillators to activate photosensitizers (PSs) to generate reactive oxygen species (ROS) for combinational RT and photodynamic therapy (PDT).[51] Moreover, X-ray radiation can be used in concert with immunotherapy to stimulate a patient’s immune system to target cancer.[52–54] All of these RT-based multimodal synchronous/synergistic therapeutic regimens have better tumoricidal effects than RT alone and serve as viable alternatives to conventional therapeutic modalities with precise on-demand treatment of deep-seated tumors.\nThe accurate diagnosis of cancer is the critical first step of any successful anticancer strategy. Noninvasive imaging modalities that have the potential to detect oligometastatic diseases are preferred.[55–60] Featuring deep tissue penetration, high spatial resolution, and low cost, X-ray computed tomography (CT) has been used extensively in the clinic for cancer diagnosis.[61–64] However, due to the limited difference in density between cancer and stromal tissues, special CT contrast agents (CAs) are required to obtain contrasted images that enable the discrimination of lesions.[65,66] In contrast to conventional CAs, which are small iodinated molecules, engineered nanosized CAs containing high-Z elements have prolonged blood circulation and enhanced tumor accumulation leading to better cancer detection.[67–69] Scintillating nanoparticles (SCNPs) can convert X-ray radiation into UV–vis light,[70–73] which enables X-ray-excited optical luminescence (XEOL) imaging. XEOL offers higher resolution and sensitivity than UV–vis or near-infrared (NIR) light-excited luminescence imaging methods,[74,75] thus promising enormous application potential.\nIt is well established that X-ray radiation is an indispensable tool for cancer management. More importantly, the advancements in nanotechnology have expanded the applications of X-ray radiation beyond traditional CT/RT. Herein, we present a comprehensive overview on the progresses made on the nanotechnology application of X-ray-excited imaging/treatment paradigms. We focus on emergent nanoplatforms for enhanced CT imaging, high-sensitivity XEOL imaging, and X-ray-excited multimodal synchronous/ synergistic therapy (RT in combination with chemotherapy/gas therapy/photodynamic therapy/immunotherapy). The featured biomedical applications of these X-ray-excited deep theranostic methodologies are also introduced. Finally, the critical issues and technical challenges pertinent to this research field will be discussed in hopes of speeding up the clinical translation of such novel theranostic technology. We believe this cross-disciplinary review will pique the broad interest of experts from different scientific disciplines, including chemistry, material science, biology, nanotechnology, biomedicine, and medical physics to create new advances in this fertile research field."
    }, {
      "heading" : "2. X-Ray-Excited Structural/Functional Imaging",
      "text" : "X-ray-excited imaging approaches mainly include CT and XEOL imaging, which can be categorized as structural and functional imaging, respectively. The past advances in the synthetic nanotechnology have catalyzed the emergence of a large library\nWenpei Fan received his Ph.D. degree in 2015 from Shanghai Institute of Ceramics, Chinese Academy of Sciences under the direction of Prof. Wenbo Bu and Prof. Jianlin Shi. He then worked with Prof. Xiaoyuan (Shawn) Chen at National Institutes of Health as a postdoctoral fellow since 2015. His\nresearch interest focuses on the design and synthesis of multifunctional nanotheranostics for multimodal imaging guided synergistic therapy.\nWei Tang received her B.S. degree in chemistry from the University of Science and Technology of China in 2011. In 2016, she received her Ph.D. degree in chemistry from the University of Georgia, under the supervision of Prof. Jin Xie. She then worked with Prof. Xiaoyuan (Shawn) Chen as a postdoctoral fellow\nat the Laboratory of Molecular Imaging and Nanomedicine (LOMIN) at the National Institutes of Health (NIH). Her research interest focuses on the development of multifunctional nanomedicine for cancer-specific imaging and drug delivery.\nXiaoyuan (Shawn) Chen received his Ph.D. degree in chemistry from the University of Idaho in 1999. He joined the University of Southern California as an assistant professor of radiology in 2002. He then moved to Stanford University in 2004 and was promoted to associate professor in 2008. In the summer of 2009, he joined\nthe Intramural Research Program of the NIBIB as a tenured senior investigator and chief of the LOMIN. He is interested in developing molecular imaging modalities for better understanding of early diagnosis of disease, monitoring therapy response, and guiding drug discovery/development.\nof nanomaterials with the capacity of improving the spatial resolution and sensitivity of CT/XEOL imaging, thus benefiting the accurate diagnosis of deep-seated tumors.\nAdv. Mater. 2019, 1806381\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1806381 (3 of 32)"
    }, {
      "heading" : "2.1. CT Imaging",
      "text" : "As a typical noninvasive diagnostic protocol, CT imaging can provide high-resolution 3D images to present the anatomic structure details of the body.[76–78] To amplify the differences of X-ray absorption between cancerous lesions and their surrounding normal tissues, small iodinated compounds (e.g., iohexol, iodixanol, etc.) with large X-ray absorption are routinely used in the clinic for contrast-enhanced CT imaging.[69] However, high dosages of iodinated CAs are usually injected to obtain clear CT images, which can cause high osmolality and viscosity, potential renal toxicity, and latent iodine hypersensitivity.[79] Besides, the small-molecule iodinated CAs suffer from short blood circulation through rapid kidney clearance, which impedes their use for targeted CT imaging of cancer.[61] Given that nanoparticles exhibit longtime circulation and enhanced tumor accumulation via the EPR effect and surface modification,[68,80] nanosized iodinated CAs may overcome the above limitations to cast new light on high-performance CT imaging of cancer.\nIn the past two decades, we witnessed the generation of many kinds of nanosized iodinated CAs prepared by the nanosynthetic chemistry. For example, Aviv et al. synthesized iodinated copolymeric nanoparticles with a relatively low concentration of glycidyl methacrylate (GMA) via emulsion copoly merization of\n2-methacryloyloxyethyl(2,3,5-triiodobenzoate) (MAOETIB).[81] These radiopaque iodinated copolymeric nanoparticles were utilized for the contrast-enhanced CT imaging of hepatic cancers. DeKrafft et al. designed iodinated metal-organic frameworks (MOFs) via coordination-directed self-assembly of 2,3,5,6-tetraiodo-1,4-benzenedicarboxylic acid (I4-BDC-H2) bridging ligands and Cu/Zn ions for CT imaging.[82] However, the MOF-based CAs were not stable and gradually decomposed in PBS solution. Considering the relatively high stability of liposomes, Ghaghada et al. developed long-circulating iodinated liposomes for high-resolution cancer CT imaging,[83] which facilitated the visualization of newly formed tumor vasculature. Besides, iodixanol-containing PEGylated liposomes were prepared by Gelovani et al. for visualization of primary lung tumors.[84]\nRecently, Zou et al. designed biocompatible and biodegradable iodinated nanopolymersomes with high stability and low viscosity via self-assembly of poly(ethylene glycol)b-poly(iodine trimethylene carbonate) (PEG-b-PIC) diblock copolymer (Figure 1a).[85] These iodine-rich nanopolymersomes (IPs) exhibited an ultrahigh iodine content (60.4 wt.%) and 1.2-fold higher CT contrast efficacy than Iobitridol (Figure 1b). The IPs with a hydrodynamic size of 100 nm could be taken up by the reticuloendotheial system (RES), as demonstrated by the intense CT signal in both liver and\nAdv. Mater. 2019, 1806381\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1806381 (4 of 32)\nspleen (Figure 1c,d). After conjugation with a cRGDfK cyclic peptide, the cRGD-IPs could specifically target integrin αvβ3overexpressing B16 melanoma xenografts, which resulted in approximately 17-fold CT imaging contrast enhancement at 4 h post injection compared to Iobitridol (Figure 1e,f). In the same paper, the authors also showed the cRGD-IPs were able to detect nodules in the orthotopic A549 lung tumor model. Preliminary data suggest that these cRGD-IPs have the potential to act as a tumor-selective CT CA for the early diagnosis of different malignancies.\nIn addition to iodinated polymeric nanoparticles, MOFs, liposomes, and nanopolymersomes, heavy metal-based nanoparticles have also been explored for contrast-enhanced CT imaging. Featured with large X-ray mass attenuation coefficient, good biocompatibility, relatively long blood circulation, and improved EPR effect, these high-Z element-contained nanomaterials (Table 1) demonstrate much higher CT contrast efficiency with respect to conventional iodinated CAs. Of those, Au nanoparticles may be the most popular metalbased CAs for contrast-enhanced CT imaging in vivo due to their low toxicity and high X-ray absorption coefficient.[86–88] Moreover, Au nanoparticles with suitable surface modification can be used for molecular targeted-imaging. For example, 2-deoxy-D-glucose (2-DG)-coated Au nanoparticles showed higher tumor cell uptake than uncoated ones because of the faster glucose metabolism of tumor cells.[89] Considering the upregulated expression of epidermal growth factor receptor (EGFR) in tumor cells, Reuveni et al. engineered Au nanoparticles with anti-EGFR antibody for targeted CT imaging.[90] Besides, Bi-based nanomaterials also hold great promise as excellent CT CAs due to their high atomic number and great X-ray attenuation ability. In 2006, Rabin et al. developed polymer-coated Bi2S3 nanoparticles with large X-ray absorption (fivefold increase relative to iodine) and long circulation times in vivo (over 2 h).[91] This enabled contrast-enhanced CT imaging of the vasculature, liver and\nlymph nodes. Ai et al. developed a facile thermal decomposition method for the large-scale controllable synthesis of ultrasmall Bi2S3 nanodots.[92] These hydrophobic nanodots could be transferred to water phase through a versatile ligand exchange strategy to yield biocompatible PVP-coated Bi2S3 nano dots, which showed great potential for CT angiography and cancer imaging. Due to its high biocompatibility and low cost, Ta-based CAs were promising for clinical CT imaging application.[93] For instance, Freedman et al. synthesized radiopaque Ta2O5 nanoparticles for in vivo CT imaging of articular cartilage.[94] Other high-Z element (W, Eu, Dy, Yb, Lu, Gd, Pt, Ho) containing nanomaterials have also been successively explored as CT CAs with greater contrast than Iobitridol.[95–101] Nevertheless, the potential toxicity of these heavy metal ion containing nanomaterials should not be ignored and must be evaluated with more efforts.\nUpconversion nanoparticles (UCNPs) are based on lanthanides with high atomic numbers that not only enhance CT contrast, but also mediate luminescence (UCL) and magnetic resonance (MR) imaging for multimodal imaging. For instance, Liu et al. synthesized Er3+/Gd3+ codoped NaYbF4 nanoparticles through a typical thermolysis method (Figure 2a).[109] The doping of Gd3+ into the NaYbF4 lattice helped control the size and morphology of nanoparticles, and afforded MRI capability. Through surface modification with DSPE-PEG 2000, the as-prepared hydrophilic PEG-UCNPs exhibited about twofold higher CT contrast than Iobitridol (Figure 2b,c), allowing for clear visualization of the spleen and liver. To further improve CT contrast, Xing et al. codoped Ba and Yb into BaYbF5:Er nanoparticles (UCA) that were synthesized through a typical hydrothermal method.[31] After DSPE-PEG modification, the CT contrast of UCA (Figure 2d) was about three folds higher than that of Iobitridol (Figure 2e,f). Following conjugation of targeting RGD peptides, the blood circulation half-life of UCA-RGD was 2 h (Figure 2g). Moreover, in contrast to UCA (non-\ntargeted group) that induced a mild HU value enhancement of 17.5 (from 29.4 to 46.9), the UCA-RGD (targeted group) could remarkably increase the average HU value of U87MG tumor from 24.0 to 67.4 (Figure 2h). The 2.5-fold amplification in the average HU value enhancement of tumor (Figure 2i) was consistent with the 3.3-fold enhancement of tumor accumulation of UCA-RGD relative to UCA (Figure 2j). Therefore, the well-established UCA-RGD could be used for targeted contrast-enhanced CT imaging of cancer.\n2.2. X-Ray-Excited Optical Luminescence (XEOL) Imaging\nXEOL imaging is based on scintillating nanomaterials (Table 2) that can convert X-ray radiation into UV–vis–NIR light. After absorbing X-ray, scintillating nanomaterials convert the radiation energy into a great\nAdv. Mater. 2019, 1806381\nTable 1. List of high-Z elements and their representative nanomaterials as CT CAs.\nElement Atomic number X-ray mass attenuation coefficient at 100 keV [cm2g−1]\nRepresentative nanomaterials Refs\nI 53 1.94 Iodine-rich nanopolymersomes,\niodinated copolymeric nanoparticles,\npoly(iohexol) nanoparticle\n[81,85,102]\nAu 79 5.16 Au nanoparticle, Au nanorod [86,103–105]\nBa 56 2.20 BaYF5:Yb/Er, BaYbF5:Er, BaGdF5:Yb/Er [31,106–108]\nYb 70 3.88 NaYbF4:Er, NaYbF4:Tm, Yb2O3:Er [95,109–111]\nLu 71 4.03 NaLuF4:Yb/Er, NaLuF4:Gd/Yb/Er [98,112]\nGd 64 3.11 Gd2O3:Yb/Er, GdOF:Yb/Er, NaGdF4:Dy [99,113,114]\nW 74 4.44 W18O49, WO3, WO3−x, WS2 [97,115–118]\nBi 83 5.74 Bi2S3, Bi2Se3, FeBi [91,119–124]\nTa 73 4.30 Ta2O5, TaOx [93,94,125,126]\nPt 78 4.99 FePt [100]\nEu 63 3.04 EuOF:Sm [127]\nDy 66 3.36 NaDyF4:Lu [96]\nHo 67 3.49 NaHoF4 [101]\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1806381 (5 of 32)\nnumber of electron–hole pairs, which are then transferred to the activated luminescent ions in the scintillating nanomaterials. When the luminescent ions return from the excited high energy state to the ground state, they emit UV–vis–NIR luminescence.[128,129] Due to the insignificant scattering and high soft tissue penetration of X-ray, XEOL allows for deep optical imaging in vivo with ultrahigh spatial resolution and negligible tissue autofluorescence.[130–132]\nLanthanide-doped fluoride-based nanoparticles (ALnF4, A = alkaline, Ln = lanthanide) are also known as UCNPs for photo-upconversion.[140–142] The fluoride matrix facilitates X-ray radiation energy transfer from self-trapped excitons (STEs) to the activator ions for luminescence emission, so ALnF4 nanoparticles can also act as scintillating nanomaterials for downconversion of X-ray into UV–vis–NIR luminescence emission. For example, Sudheendra et al. investigated the X-ray-activated luminescence emission from NaGdF4:Eu scintillating nanoparticles (Figure 3a).[138] They found that the X-ray-activated luminescence intensity of NaGdF4:Eu was dependent on the particle phase and Eu3+ doping ratio. The radioluminescence intensity\nof NaGdF4:Eu nanoparticles reached its maximum value at 15% doping concentration of Eu3+, with the hexagonal NaGdF4:Eu nanoparticles exhibiting stronger vis/NIR luminescence emission than cubic ones upon X-ray excitation (Figure 3b). The radioluminescence intensity of hexagonal NaGdF4:Eu was also higher by a factor of 2 than that of BaYF5:Eu (Figure 3c), which was confirmed by in vivo XEOL imaging in a mouse model (Figure 3d). Therefore, it is expected that NaGdF4 nanoparticles with an appropriate dopant of rare earth ions have potential for use as scintillating nanomaterials in XEOL imaging.\nAnother form XEOL imaging is luminescence emission within the second infrared window (1000–2300 nm), where X-ray-excited shortwave infrared (SWIR or NIR-II) imaging provides high-resolution visualization of deep-seated biological structures due to the reduced autofluorescence, attenuated photon scattering, and deep tissue penetration.[143,144] Rareearth doped nanoprobes (REs) can be used for SWIR molecular imaging upon X-ray excitation, to reduce background signal and to simplify the reconstruction of optical images. Naczynski et al. reported the design of core–shell structured\nAdv. Mater. 2019, 1806381\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1806381 (6 of 32)\nNaYF4:Yb/Er@NaYF4 nanoparticles as REs (Figure 4a,b) for X-ray-excited deep SWIR (X-IR) imaging.[145] The sensitizer Yb3+ absorbed and transferred X-ray radiation energy to the SWIR activator Er3+, which resulted in SWIR luminescence emission. The REs exhibited a characteristic SWIR peak emission at 1525 nm upon X-ray activation (Figure 4c), and the X-IR emission intensity correlated positively with REs concentration and applied X-ray accelerating voltage (Figure 4d,e). The\nX-IR imaging of REs was applied for mapping lymphatic drainage. When PEG-modified REs were injected into the forepaw pad of mice, the X-IR signal was localized into the lower limb and appeared in two distinct regions near the draining lymph nodes (Figure 4f,g). Such sentinel lymph node mapping contributes greatly to detecting cancer metastases by visualizing lymph nodes near a primary tumor site under the assistance of high-resolution X-IR imaging.\nMost scintillating nanomaterials can only emit luminescence upon X-ray irradiation but cease any emission when the excitation source is removed. However, there is a distinct type of scintillating nanomaterial, X-ray-excited persistent luminescence nanoparticles (PLNPs), which can still emit long-lasting phosphorescence (afterglow)\nafter X-ray irradiation.[146] During this particular scintillating process, the ionizing radiation energy is stored at the electron traps or surface defects during the X-ray irradiation. Then the stored radiation energy is converted to the UV–vis–NIR luminescence for afterglow emission at the end of X-ray irradiation. Cu2+ and Co3+ codoped ZnS nanoparticles have been reported to generate Vis afterglow (range from 400–600 nm) after X-ray excitation.[146,147] By comparing the afterglow intensity of ZnS\nAdv. Mater. 2019, 1806381\nTable 2. List of scintillating nanomaterials and their characteristics.\nScintillating nanomaterials Size Excitation source\nEmission wavelength\nRefs\nLiYF4:Ce nanoparticles ≈20 nm X-ray 300–350 nm [133]\nSrAl2O4:Eu nanoparticles ≈80 nm X-ray 450–600 nm [134]\nLaF3:Tb nanoparticles ≈40 nm X-ray 450–600 nm [135]\nTb2O3 nanoparticles ≈4 nm X-ray 450–650 nm [51]\nCeF3 nanoparticles ≈9 nm X-ray 300–450 nm [136]\nY2O3 nanoparticles ≈12 nm X-ray 300–500 nm [137]\nNaGdF4:Eu nanoparticles ≈30 nm X-ray 550–750 nm [138]\nBaYF5:Eu nanoparticles ≈30 nm X-ray 550–750 nm [138]\nGd2O2S:Tb ellipsoidal nanocapsules length of ≈420 nm, width of ≈130 nm\nX-ray 450–700 nm [75]\nGd2O2S:Eu nanoparticles ≈40 nm X-ray 500–750 nm [139]\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1806381 (7 of 32)\nnanoparticles with different doping concentrations of Cu2+ and Co2+, Ma et al. found that the optimal dopants for ZnS nanoparticles were 0.003% Co2+ and 0.07% Cu2+, which exhibited the strongest afterglow emission.[148] Song et al. observed the NIR afterglow emission (peaking at 696 nm) from ZnGa2O4:Cr nanoparticles at the end of X-ray excitation.[149] Moreover, further doping of W into ZnGa2O4:Cr nanoparticles (ZnGa2O4:Cr/W) could enhance the X-ray absorption efficiency and offer additional electrons to increase the afterglow intensity and prolong the afterglow decay time.\nChen et al. designed a LiGa5O8:Cr (LGO:Cr)-based nanoscintillator and explored its application in the X-ray-activated afterglow imaging in vitro and in vivo.[150] The LGO:Cr nanoparticles (Figure 5a) were synthesized through a polystyrene sphereassisted sol-gel method. After mesoporous silica coating, the resulting LGO:Cr@mSiO2 nanoparticles demonstrated NIR afterglow emission centered at about 720 nm when X-ray radiation was turned off (Figure 5b), and the afterglow lasted for more than 30 min (Figure 5c). The deep afterglow imaging was simulated by placing the LGO:Cr@mSiO2 nanoparticles below a 1.5 cm thick slice of pork meat. Figure 5d showed that the persistent NIR luminescence from LGO:Cr@mSiO2 nanoparticles was detectable from under 1.5 cm of pork meat. Moreover, LGO:Cr@mSiO2 nanoparticles could be repeatedly “charged” to emit NIR afterglow with negligible luminescence signal loss (Figure 5e). It should be noted that this X-ray-activated afterglow imaging demonstrated almost zero autoluminescence since there was no X-ray excitation during the detection of afterglow. To investigate the tissue penetration ability of X-ray-activated NIR afterglow imaging, LGO:Cr@mSiO2 nanoparticles were intramuscularly injected into the hind leg of a nude mouse. After X-ray irradiation, the\nin vivo afterglow signals were detected and gradually attenuated over time (Figure 5f). Excitingly, the quality of in vivo afterglow imaging was not compromised from repeated X-ray excitation (Figure 5g), which confirmed the unique advantage of LGO:Crbased nanoscintillator in repeated high-resolution afterglow imaging with minimal background after cyclical X-ray activation. The unique afterglow emission with almost zero autofluorescence enables X-ray-excited PLNPs to be a distinct and prominent nanoscintillator for deep XEOL imaging as well as afterglow imaging with high signal-to-noise ratio. However, the afterglow intensity and decay lifetime need to be markedly enhanced before potential clinical translation. This can be potentially achieved by fabricating core–multishell structures with decreased surface defects, which will benefit the highresolution optical imaging-mediated diagnosis as well as effective X-ray-excited deep therapy."
    }, {
      "heading" : "3. X-Ray-Excited Synchronous/Synergistic Therapy",
      "text" : "Distinct from the low-energy X-ray (approximately keV) used for CT imaging, high energy X-ray radiation (approximately MeV) is used to directly damage DNA and suppress the proliferation of cancer cells via RT. Moreover, there exist cooperative enhancement interactions between RT and other treatments, which lay the foundation for RT-based multimodal synergistic therapy. For example, some chemotherapeutic agents (e.g., cisplatin, PTX, etc.) can amplify the localized X-ray doses via the Compton scattering effect or trap the cells within the G2/M phase (most sensitive to ionizing radiation) to improve the radiotherapeutic effect for synergistic RT/chemotherapy.[151–153]\nAdv. Mater. 2019, 1806381\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1806381 (8 of 32)\nSome gasotransmitters (e.g., O2, NO, H2S, etc.) can act as radiosensitizers to remarkably increase the sensitivity of the hypoxic cells to X-ray radiation for enhanced RT efficacy,[154–157] which leads to synergistic RT/gas therapy. Moreover, the ROS arising from PDT can inhibit the DNA repair of cancer cells following exposure to RT,[45,46] which provides an opportunity for synergistic RT/PDT. Although these RT-based synergistic treatments can supress tumor growth and even lead to tumor regression in preclinical models, there are potential limitations. Systemic chemotherapy treatment can cause adverse effects, while UV– vis light-excited PDT suffers from low tissue penetration ability and fails to treat deep-seated tumors.[158,159] To realize synergistic therapeutic output, it may be preferable to have the independent treatment modalities to be simultaneously present. As such, current researches on RT-based synergistic therapy have been gradually shifted to RT-based synchronous therapy through the excitation of two or more therapeutic modalities controlled by a single X-ray radiation source. Recent studies show that high-energy X-ray radiation can break down the low-energy bonds for releasing anticancer drugs and gas molecules for X-ray-excited synchronous/synergistic RT/chemotherapy and RT/gas therapy, respectively. X-ray can indirectly activate PSs to produce ROS for synchronous/ synergistic RT/PDT by means of X-ray-to-light conversion via nanoscintillators. Moreover, X-ray radiation can improve the immune responses for synchronous/synergistic RT/immunotherapy. All of these well-developed X-ray-excited multimodal therapeutic techniques contribute greatly to the efficient ondemand treatment of deep-seated tumors by only changing the imposed X-ray radiation doses.\nAdv. Mater. 2019, 1806381\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1806381 (9 of 32)"
    }, {
      "heading" : "3.1. RT/Chemotherapy",
      "text" : "As mentioned previously, high energy X-ray can break the DNA strands and low energy bond-composing polymeric nanoparticles for controlled release of anticancer drugs for synchronous RT/chemotherapy. X-ray-activated drug release is beneficial for preventing premature drug leakage and confining drug delivery to target sites. Just as important, the amount of drug released can be precisely controlled by adjusting X-ray radiation dose and duration.\nStarkewolf et al. designed an X-ray-responsive nanoparticle drug carrier (NDC) by conjugating DOX to the surface of gold nanoparticles through the bridge of DNA strands.[49] Once the NDC was taken up into cancer cells, applied radiation cleaved the DNA strands to release DOX for simultaneous RT and chemotherapy. Increasing radiation dose enhances the rate of DOX release, which further increases the cytotoxicity of NDC. Ma et al. found that γ-radiation could cause SeSe bond scission leading to the decomposition of diselenide-containing block copolymer (PEG-PUSeSe-PEG) aggregates. This helped release the encapsulated DOX from the aggregates (Figure 6a).[50] The transmission electron microscopy (TEM) images of PEGPUSeSe-PEG aggregates before and after γ-ray radiation (Figure 6b,c) provided direct evidence for radiation-activated disassembly of diselenide-containing aggregates. Moreover, higher dose of γ-ray radiation accelerated the disintegration of PEGPUSeSe-PEG aggregates, which was accompanied by a larger release of DOX (Figure 6d). The authors studied the mechanism behind the radiation-responsive disassembly of PEG-PUSeSePEG aggregates by Fourier Transform infrared spectroscopy (FTIR) analysis of the products. It was concluded that the\nradiolysis of water generated oxidative species (Figure 6e), which oxidized the diselenide groups within the aggregates into seleninic acids (as shown by the emerging absorption band at 880 cm−1 in the FTIR spectra of Figure 6f). The SeSe bond could also be directly cleaved by X-ray irradiation. These two pathways accounted for the radiation-controlled drug release. Later, Meng et al. designed X-ray-sensitive liposomes through the coassembly of phospholipid and di-(1-hydroxylundecyl) diselenide.[160] The liposomes had high DOX encapsulation efficiency of 75.84%. X-ray irradiation oxidized the diselenide group into seleninic acid and thus broke the liposome to release the encapsulated DOX. The DOX release percentage increased with elevated X-ray dose and reached ≈60% upon the irradiation of 30 Gy X-ray. The technique of X-ray dose-dependent drug release will be helpful to realize on-demand synchronous/synergistic RT/chemotherapy at deep sites with few side effects.\nDespite the higher bonding energy of SS bond (240 kJ mol−1) than SeSe bond (172 kJ mol−1), X-ray can also cause the reduction at the SS bond via an exchange reaction to induce the disassociation of disulfide-linked aggregates. Tanabe et al. used the X-ray-sensitive disulfide bond to connect oligodeoxynucleotides (ODNs, a hydrophilic component) and an alkyl chain (a hydrophobic component) to construct DNA amphiphiles (DAMs).[161] The DAMs could self-assemble to form nanosized aggregates for loading hydrophobic dyes and drugs. Upon X-ray irradiation, DAM 1 turned into DAM 1a via strand exchange reaction, which resulted in the dissociation of the DAM aggregates and release of the encapsulated dyes and drugs (Figure 7a,b). Meanwhile, the yield of DAM 1a from the X-ray-activated reduction of DAM 1 increased as a function of X-ray dose (Figure 7c). When pyrene was encapsulated into\nAdv. Mater. 2019, 1806381\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1806381 (10 of 32)\nthe DAM 1 aggregates, the fluorescence intensity of pyrene decreased (Figure 7d) following X-ray irradiation, which indicated the release of pyrene from the disintegrated aggregates through an exchange reaction of disulfide bond. Finally, the authors evaluated the cytotoxicity of CPT-loaded DAM 1 aggregates in hypoxic A549 lung cancer. As expected, the combination of X-ray and CPT-loaded DAM 1 had higher cytoxicity than either modality alone (Figure 7e) because of the radiolytic degradation of the DAM 1 aggregates and the subsequent release of CPT. As such, the disulfide-composing DAM 1 aggregates may act as an advanced X-ray-responsive nanocarrier for radiation dose-controlled drug delivery/release.\nRecently, our group introduced X-ray-activated drug release with DOX-loaded Au nanovehicles.[162] The X-ray-responsive Au nanovehicles were composed of X-ray-sensitive linoleic acid hydroperoxide (LAHP) molecules and oxidation-activated poly(propylene sulfide)-poly(ethylene glycol) (PPS-PEG) polymer. X-ray triggered the heterolytic scission of peroxide bond in LAHP to generate •OH (Figure 8a), which in turn oxidized the hydrophobic PPS into hydrophilic PPS. This culminated in the disassociation of Au nanovehicles and subsequent release of the loaded DOX (Figure 8b–d). The Au-LA-vDOX without hydroperoxide group had limited DOX release in response to X-ray irradiation, while Au-LAHP-vDOX demonstrated burst DOX release upon X-ray irradiation (Figure 8e). This confirmed the key role of X-ray-activated •OH generation from the hydroperoxide group in the decomposition of the Au nanovehicles. Au-LAHP-vDOX was tested both in vitro (Figure 8f) and in vivo (Figure 8g) using the U87-MG glioblastoma model. By\ncomparison with Au-LA-vDOX, the X-ray-responsive Au-LAHPvDOX exhibited much higher cytotoxicity upon X-ray irradiation, which should be attributed to the increased release percentage of DOX. Moreover, Au-LAHP-vDOX in combination with X-ray thoroughly suppressed tumor growth and in some cases led to complete elimination with one treatment dose.\nApart from the above radiation-controlled drug release, X-ray can also be used to activate nontoxic prodrugs, which is beneficial for achieving synchronous/synergistic RT/chemotherapy with negligible toxicity to normal tissues. Tanabe et al. synthesized an X-ray-sensitive prodrug of 5-fluorodeoxyuridine (5-FdUrd) with an indolequinone structure (IQ-FdUrd).[163] X-ray could induce the radiolytic reduction of IQ-FdUrd into 5-FdUrd via one-electron reduction. The released 5-FdUrd was cytotoxic against hypoxic EMT6/KU cells. Moreover, the viability of EMT6/KU cells after incubation with IQ-FdUrd was decreased with elevated X-ray radiation dose, which demonstrated X-ray dose-controlled cytotoxicity of IQ-FdUrd. Later, the authors used a 2-oxoalkyl linker to connect two molecules of 5-FdUrd to obtain FdUrd2, so that two active compounds of 5-FdUrd could be released with one-electron reduction.[164] FdUrd2 was nontoxic itself but exhibited prominent cytotoxicity to A549 cells upon a large dose of X-ray irradiation, so future efforts should be made to accelerate the radiolytic release of 5-FdUrd from FdUrd2 for enhanced chemotherapy efficacy upon low-dose X-ray irradiation. Aiming at efficient tumor-specific delivery, these prodrugs should be loaded into advanced nanocarriers for enhanced tumor uptake via the EPR effect. This X-ray-controlled prodrug activation strategy will be highly\nAdv. Mater. 2019, 1806381\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1806381 (11 of 32)\nvaluable for on-demand deep synchronous/synergistic RT/ chemotherapy through the precise regulation of X-ray doses."
    }, {
      "heading" : "3.2. RT/Gas Therapy",
      "text" : "As an emerging treatment, gas therapy involves the use of gasotransmitters to trigger cancer cells death.[156] The outstanding merit of high biosafety makes gas therapy regarded as a “green” therapeutic modality with negligible adverse effects on normal tissues.[165] Nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide (H2S) are the three main gasotransmitters explored for inducing cancer cell death.[166–170] Nowadays, various types of stimuli-responsive NO/CO/H2S donors have been designed for controlled release of gasotransmitters at designated sites.[171] For examples, some gas donors are delivered in response to endogenous stimuli like pH change or GSH level in the tumor microenvironment (TME) for cancer-specific gas therapy.[172–174] Due to the heterogeneity and biological variations that exist from tumor to tumor, it is difficult to accurately predict dose delivery using these endogenous stimuli. Subsequently, it is more appealing to use an exogenous stimulus to control gasotransmitter release.[175–178] By comparison with the limited tissue penetration of light and potential tissue attenuation of ultrasound, the highly penetrating X-ray exhibits the unique advantage in controlling the gasotransmitter release at deep sites both spatially and temporally, which is beneficial for on-demand gas therapy of deep-seated malignant tumors. Bu and co-workers presented an example of X-ray-responsive NO release from the S-nitrosothiol (SNO)-grafted UCNP@mSiO2 nanostructure (denoted as PEG-USMSsSNO, Figure 9a).[179] Owing to the lower bond energy of SN (150 kJ mol−1) than SeSe (172 kJ mol−1), the SN bond within the SNO group could be preferentially cleaved to release NO molecules. The released NO concentration showed positive correlation with the X-ray dose (Figure 9b). The underlying mechanism behind the X-ray-activated NO release could be attributed to the ROS generation (as a result of radiolysis of water) which attacked the SN bond to trigger NO release. As the generated ROS concentration was dependent on the X-ray dose, the released NO amount was also increased with the elevated X-ray dose. The authors found that the X-ray-controlled NO release worked in both normoxic (21% O2) and hypoxic (2% O2) HeLa cells. The in vivo NO release was studied in optically transparent zebrafish larvae. As shown in Figure 9c, the NO signal (probed by 3-amino-4-aminomethyl-2′,7′-difluorescein diacetate, DAF-FM DA) appeared in the brain of zebrafish larvae after microinjection of PEG-USMSs-SNO and X-ray irradiation. The intensity of NO signal increased with elevated doses of X-ray irradiation as well (Figure 9c1–c5). Subsequently, the authors evaluated the therapeutic efficacy of PEG-USMSs-SNO with X-ray irradiation in 4T1-tumor bearing mice. NO was reported to act as a gaseous radiosensitizer to increase the sensitivity of hypoxic cells to ionizing radiation, so the treatment of PEG-USMSs-SNO + RT gave rise to significant NO-sensitized radiotherapeutic effects on substantial tumor growth delay\nAdv. Mater. 2019, 1806381\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1806381 (12 of 32)\n(Figure 9d). The well-developed technique of X-ray dosedependent NO release may enable the on-demand synchronous/synergistic RT/gas therapy of deep-seated tumors.\nBesides direct excitation, X-ray can also indirectly activate the gas donors to release gasotransmitters for synchronous/ synergistic RT/gas therapy by taking advantage of the X-rayto-light conversion of scintillators. Very recently, Du et al. designed a multifunctional X-ray-responsive NO release nanoplatform (RBS-T-SCNPs) through the construction of SCNP (LiLuF4:Ce) and a UV-sensitive NO donor (Roussin’s black salt, RBS) (Figure 10a).[180] The tocopheryl polyethylene glycol 1000 succinate (TPGS) was attached onto the surface of LiLuF4:Ce nanoparticles (T-SCNPs) for improved biocompatibility. The match-up between the radioluminescence emission (290–363 nm) of T-SCNPs and UV absorbance of RBS (Figure 10b) allowed for the efficient transfer of X-ray-induced photons in between, which resulted in the decomposition of RBS molecules for NO generation. Figure 10c showed that X-ray could control both the “on/off” NO generation behavior and dose-dependent NO release behavior, which meant that the released NO amount could be precisely controlled by adjusting X-ray doses. Besides, X-ray could also activate the RBS-T-SCNPs to generate NO in A549 cells, as shown by a strong green fluorescence signal of intracellular NO (Figure 10d). In addition to X-ray-responsive NO release from RBS-T-SCNPs, the SCNPs containing high-Z elements (Lu) could act as a radiosensitizer to increase the O2−• yield because of the strong X-ray attenuation for accelerating the radiolysis of water. Therefore, the X-ray-excited concurrent release of O2−• and NO resulted in the generation of ONOO−. ONOO− exhibited much higher toxicity toward A549 cells than O2−• (Figure 10e). As ONOO− could inhibit the PARP-associated DNA-repair and augment the DNA damage for enhanced RT (Figure 10f,g), the treatment of\nRBS-T-SCNPs + X-ray produced a noticeable therapeutic effect on thorough suppression of A549 tumor growth (Figure 10h). It is expected that the X-ray-controlled simultaneous release of O2−• and NO may provide a new strategy for realizing enhanced on-demand synchronous/synergistic RT/gas therapy of deep cancer."
    }, {
      "heading" : "3.3. RT/PDT",
      "text" : "PDT is a clinically approved and relatively noninvasive treatment protocol for cancer management.[181] It consists of three key components: light, oxygen, and PS.[182] When irradiated with a light at specific wavelength, the nontoxic PSs will transfer light energy to nearby oxygen molecules, generate cytotoxic ROS, most importantly singlet oxygen (1O2), and kill cancer cells.[183–185] One major concern of PDT, however, is the limited light penetration in tissues and the unsatisfactory treatment efficacy on deep-seated tumors.[158] To solve this problem, X-ray is introduced as a promising excitation source to break the restrictions of the shallow tissue penetration.[186,187] The X-ray induced PDT (X-PDT) is not only a simple PDT derivative, but a synchronous combination of PDT and RT.[48,188] However, no PSs can be directly activated by X-ray because their excitation wavelength doesn’t match with X-ray energy.[189] To bridge the gaps between X-ray radiation and PS activation, nanoscintillators that can convert X-ray into UV–vis light are widely used. Several strategies can be employed to attach PSs to nanoscintillators, for example, encapsulation into porous silica structures,[48] covalent conjugation onto the particle surfaces via carbonyl/amine/thiol coupling reactions,[51,137,190,191] physical loading into polymer coating layers based on either hydrophobic interactions or electrostatic adherence.[136,192]\nAdv. Mater. 2019, 1806381\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1806381 (13 of 32)\nTo achieve effective X-PDT, the PS-scintillator nanoplatform should have excellent water-solubility, high stability, negligible toxicity, and most prominently, a good overlap between the nanosintillator emission and the PS absorption.\nThe first X-PDT nanoagents were reported by Chen et al. in 2006.[187] They attached scintillation nanoparticles with PSs such as porphyrins, bis-cyclometallated Ir(III) complexes, fullerenes, and TiO2 or ZnO semiconductor nanoparticles for in vivo PDT treatment. Upon X-ray irradiation, the nanoparticles converted X-ray energy into UV or Vis photons, which was the phenomenon known as XEOL. XEOL, in turn, activated the PSs, resulting in efficient 1O2 generation and effective cancer cell killing. Since then, several rare-earth-element-based nanoparticles (e.g., LaF3:Ce, LaF3:Tb, Tb2O3, Gd2O2S:Tb, etc.) have been used as X-ray converter in X-PDT.[51,190,192,193]\nRecently, Xie and co-workers conducted systematic studies on X-PDT with SrAl2O4:Eu2+ (SAO) nanosystems (Figure 11a).[48,134] The SAO was coated with an inner solid silica layer to prevent hydrolysis of SAO and an outer mesoporous silica layer to load PSs (Figure 11b,c).[134] MC540 was chosen as the PS, because of the excellent match-up of its excitation wavelength with the XEOL of SAO at around 520 nm (Figure 11d). Successful 1O2 generation of the MC540-loaded and silica-coated SAO (M-SAO@SiO2) nanoparticle was demonstrated with singlet oxygen sensor green (SOSG) assays. Upon X-ray irradiation, the M-SAO@SiO2 solution induced 8%, 35%, and 59% SOSG fluorescence increase at 5, 15, and 30 min, respectively. In contrast, solutions containing MC-540, SAO, or PBS showed no significant fluorescence change after irradiation (Figure 11e), suggesting that MC-540, SAO, and X-ray are three indispensable components for the 1O2 production. It was the SAO-regulated energy transfer rather than X-ray itself that activated the PS. Next, the authors examined the X-PDT cancer killing effect both in vitro and in vivo with a low X-ray dose. The MTT assays on U87MG cells observed little toxicity in controls but a 62.0 ± 9.0% viability drop in the X-PDT-treated cells (0.5 Gy, single dose, Figure 11f). When tested in vivo on U87MG-tumorbearing mice, the X-PDT (1 Gy h−1, 30 min) induced significant tumor suppression and shrinkage (Figure 11g). The biosafety profile of M-SAO@SiO2 was also evaluated by examining the Sr content biodistribution after therapy. No obvious difference was found between M-SAO@SiO2 and PBS control groups,\nAdv. Mater. 2019, 1806381\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1806381 (14 of 32)\nsuggesting successful degradation and excretion of SAO. The data suggested that X-PDT reduced both short-term cell viability and long-run clonogenicity, suggesting an essential synchronous combination of PDT and RT.[48] The authors found a significant cell viability drop after 24 h incubation of M-SAO@SiO2 nanoparticle-treated H1299 cells with an elevated X-ray dose. In contrast, no significant cell death was observed after 24 h of RT alone (0–5 Gy). In addition to the short-term cell viability with MTT assays, the authors also assessed the cell reproductive capacity with clonogenic assays, finding a 1.67-fold dose enhancement factor (DEF) of X-PDT than RT. These results inspired the authors to investigate the cause of the cell death in X-PDT from the perspectives of the different cellular targeting components of PDT and RT—the cell membrane for PDT and DNA for RT. After X-ray irradiation (5 Gy), the lipid peroxidation level was increased by 201.5 ± 34.0% and 90.5 ± 23.0% in X-PDT and RT treatment group, respectively (Figure 11h), implying PDT-induced oxidative degradation of unsaturated lipids and surface proteins in X-PDT. In the meantime, the comet assays showed a more extensive DNA double-strand break in X-PDT relative to RT (Figure 11i). The Western blot results demonstrated enhanced expression of both Cox-2 and H2AX after X-PDT, further confirming PDT-induced upregulation of lipid peroxidation and RT-induced DNA damage in X-PDT (Figure 11j). When tested in H1299-tumor-bearing mice, effective tumor suppression was observed even when covering the tumor with a 2 cm pork tissue block (Figure 11k), which was attributed to a synergy of PDT and RT in the X-PDT treatment. Although the results of the two studies were impressive, several improvements are still possible in the design of M-SAO@ SiO2. First, the M-SAO@SiO2nanoparticle was tested in vivo by intratumoral injection in both cases. Further optimization of the nanoparticle formulation should be performed to increase their physiological stability, cellular uptake, and active tumor targeting capability to meet the requirements of intravenous injection.\nAdv. Mater. 2019, 1806381\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1806381 (15 of 32)\nApart from rare-earth-element-based nanoparticles, metalbased nanoparticles can also work as X-ray sensitizers. For example, Ma et al. developed an X-ray-excited Cu/CO codoped ZnS (ZnS:Cu/CO) afterglow nanoparticle to activate tetrabromorhodamine-123 (TBrRh123).[146] The nanosystem had an efficient energy transfer and long-lasting afterglow, which allowed for persistent PDT activation even after X-ray was turned off, exhibiting a high light-to-dark ratio cytotoxicity in a preliminary experiment on PC-3 (human prostate cancer cell line) cell study. In another example, Cheng and co-workers reported dumbbell-like Au-TiO2 nanoparticles (DATs) for synergistic RT and PDT.[188] Upon X-ray irradiation, the high-Z Au nanoparticles could induce secondary photons or electrons generation, which on the one hand sensitized RT, and on the other hand, migrated to TiO2 nanoparticles to facilitate ROS production for PDT. A high level of ROS generation was observed in vitro upon X-PDT treatment with the Au-TiO2 nanoparticles, resulting in widespread apoptotic cancer cells. When tested in triple-negative breast tumor models, the DAT-mediated X-PDT significantly reduced the tumor growth (sixfold reduction in average tumor volume relative to untreated group) and extended the median survival to more than 110 d. In this case, the mechanism of ROS production from TiO2 nanoparticles diminished the oxygen-dependence of conventional PDT. Therefore, although not examined, this DAT nanoformulation is expected to show excellent cancer killing efficacy in a hypoxic environment. In addition, metal–organic framework (MOF)-based nano particles can also be used as X-ray converter. Lan et al. designed ultrathin metal-organic layers (MOLs) that were composed of [Hf6O4(OH)4(HCO2)6] secondary building units (SBUs) and high potent PSs of Ir[bpy(ppy)2]+ or [Ru(bpy)3]2+ for X-PDT in colon cancer treatment (Figure 12a).[186] The resulting HfBYP-Ir or Hf-BYP-Ru MOLs showed similar morphologies and sizes in TEM images (Figure 12b,c). Atomic force micro scopy (AFM) analysis suggested a monolayer Hf-BYP structure with a thickness of around 1.2 nm (Figure 12d,e). X-ray-induced 1O2 generation from the Hf-MOLs was determined by using 4-nitroso-N,N-dimethylaniline (RNO) assay. By comparison with the corresponding Zr-MOL controls, both Hf-BPY-Ir and HfBPY-Ru had much higher 1O2 generation efficiency (Figure 12f). As the heavier Hf atom is a more efficient X-ray absorber than the Zr atom, it was postulated that the X-PDT effect herein was regulated by the SBU-based energy transfer. Moreover, the Hf-MOLs led to excellent tumor inhibitions in subcutaneous CT26 and MC38 cancer models under low-dose X-ray irradiation (1 Gy/fraction, 5 fractions for CT26 model and 10 fractions for MC38), showing a corresponding 83.6% or 82.3% tumor\nAdv. Mater. 2019, 1806381\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1806381 (16 of 32)\nregression with Hf-BPY-Ir and a 77.3% or 90.1% inhibition with Hf-BPY-Ru, respectively (Figure 12g,h). In this unique monolayer MOL design, the heavy Hf atom plays an important role in efficient X-ray energy transfer and ROS generation. Moreover, the ultrathin layer structure can assist the efficient ROS diffusion and ensure superior anticancer efficacy of X-PDT. This novel type of MOLs represents a paradigm of 2D X-PDT agents, which holds great potential in cancer treatment and clinical translation."
    }, {
      "heading" : "3.4. RT/Immunotherapy",
      "text" : "Cancer immunotherapy promises great opportunities to cure cancer.[194–196] In particular, checkpoint blockade immunotherapy, such as anti-CTLA-4 and anti-PD-1, has effectively improved the survival of patients with head and neck, bladder, melanoma, and non-small-cell lung cancers.[197–201] Recent findings in the abscopal effect, a phenomenon where local tumor treatment induces a systemic regression of metastasis lesions,\nbridge the gap between immunotherapy and RT.[54] RT is widely used in the clinic for local tumor treatment, but is insufficient for systemic tumor suppression. The combination of RT and immunotherapy provides an opportunity to remodel tumor microenvironment and potentially make the applications of RT beyond a local treatment modality.[202] When combining RT with checkpoint inhibitor, the irradiated tumor can act as an X-ray-induced in situ vaccine, leading to expansion and infiltration of cytotoxic T cells, and ultimately the regression of primary and metastatic lesions. However, the use of nanoparticles to boost the X-ray-excited synchronous RT/immunotherapy has seldom been reported.\nMin et al. proposed to use antigen-capturing nanoparticles (AC-NPs) to bind tumor antigens after radiotherapy, therefore enhancing antigen presentation, boosting αPD-1 (antiprogrammed cell death 1) treatment efficacy, and finally eliciting the “abscopal effect” for improved cancer immunotherapy (Figure 13a).[53] They investigated the impact of surface properties of the PLGA-based AC-NPs on capturing\nAdv. Mater. 2019, 1806381\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1806381 (17 of 32)\nability of tumor-derived protein antigens (TDPAs) by using 1,2-dioleoyloxy-3-(trimethylammonium)propane (DOTAP), amine, maleimide, and PEG. All the formulations, except for mPEG AC-NPs which served as the negative control, successfully captured the neoantigens that were released after RT (Figure 13b). The sets of TDPAs captured were found to be dependent on the surface chemistry of AC-NPs. When tested on a bilateral B16F10 melanoma tumor model, PLGA and Mal AC-NPs induced the most robust therapeutic response among all treatment groups. They substantially inhibited the growth of the secondary tumors (unirradiated) and greatly prolonged the survival (Figure 13c,d). To validate that AC-NPs delivered TDPAs to antigen presenting cells (APCs), the authors injected rhodamine-labeled AC-NPs intratumorally and studied their distribution in lymph nodes. After 16 h, AC-NPs were easily detected in the nearby tumor-draining lymph nodes (TDLNs) of the primary tumors (irradiated), with higher level of fluorescence signals in both the PLGA and Mal AC-NP-treated groups (Figure 13e). To further examine T-cell activation and expansion, the relative abundance of CD8+ T, CD4+ T, and Treg subpopulations in the secondary tumors were measured 16 d after RT. Significantly increased intratumoral CD8+ T/Treg and CD4+ T/Treg ratios were found upon the addition of the PLGA and Mal AC-NPs adjuvants to αPD-1 immunotherapy, which suggested an increased T cell infiltration and antitumor immunotherapeutic activity within the secondary TME (Figure 13f). Recently, inspired by the well-known mechanism of PDTstimulated immunotherapy, Lan et al. had a follow up study of their MOL-mediated X-PDT[186] and proposed an nMOF-enabled radiotherapy-radiodynamic therapy (RT-RDT) enhanced checkpoint blockade immunotherapy.[203] The nMOF consisted of Hf clusters and porphyrin-based PS ligands (Figure 14a). The heavy-atom Hf clusters efficiently absorbed X-ray energy to induce •OH radical production for RT, which in turn, activated the PS ligands to generate 1O2 for RDT (Figure 14b). 5,15-Di(pbenzoato)porphyrin-Hf (DBP-Hf) showed a uniform nanoplate structure with a diameter of around 70 nm (Figure 14c) and a linear relationship between 1O2 generation and the product of\nAdv. Mater. 2019, 1806381\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1806381 (18 of 32)\nnMOF concentration (µM) based on RNO assay (Figure 14d). Next, the authors investigated the synergistic RT-RDT and immunotherapy with low doses of X-ray radiation (Figure 14e). It was postulated that RT-RDT would effectively induce cell apoptosis and necrosis in the primary tumors (irradiated), resulting in a robust activation of CD8+ T cells in the secondary tumors (unirradiated). Meanwhile, immunotherapy with IDOi would overcome immune suppressive microenvironment and elicit a systematic immune response to the distant tumors. The synergistic effect between RT-PDT and immunotherapy was expected to elicit abscopal effect and significantly suppress the distant untreated tumors. The abscopal effect of IDOi@DBP-Hf was investigated in both CT26 and TUBO tumor models (Figure 14f,g). In both cases, a low dose of X-ray irradiation (0.5 Gy per fraction, 6 fractions) not only resulted in local tumor eradication, but also induced substantial size shrinkage of the distant tumors, suggesting successful immune response stimulation. Further investigation on the T cell subpopulations in irradiated and unirradiated tumors found enhanced infiltrating CD8+ T cells in both tumors, which was an important contributor to the abscopal effect (Figure 14h–j). In summary, an nMOF structure was used as a RT-RDT radiosensitizer and an immunotherapeutic drug carrier. However, the physiological stability and active tumor targeting capability of MOF were primary concerns. Further optimization of nMOF structure will be needed to make it a more powerful and more clinically relevant nanoplatform for immune-/radiotherapy.\nThe X-ray-controlled drug release/activation, gasotransmitter release, ROS generation, and immune responses lay the foundation for RT-based multimodal synchronous/synergistic therapy (Table 3), which shows unparalleled advantages in radiation dosedependent on-demand precise treatment of deep-seated tumors with minimal side effects. Moreover, the synchronous use of RT and other therapeutic modalities can further maximize their cooperative enhancement interactions for achieving the optimal treatment efficacy. However, the utilization of X-ray is still low, which has become an obstacle for the further improvement of RT-based therapeutic effectiveness. Maybe the introduction of high-Z elements (e.g., Au, Ba, Bi, Pt, etc.) for amplifying the localized X-ray doses by taking advantage of the Compton scattering effects, can help address this issue by increasing the photon capturing ability and remarkably enhance the RT-based synchronous/synergistic treatment efficacy even at low dose X-ray, thus avoiding the high dose X-ray-induced radiation damage."
    }, {
      "heading" : "4. Featured Biomedical Applications of X-Ray-Excited Deep Nanotheranostics",
      "text" : "The large body permeability, precise positioning, and controllable radiation dose make X-ray a unique excitation source for deep cancer theranostics. Moreover, the introduction of nanotechnology through the judicious design of multifunctional “intelligent” nanomaterials offer great possibilities for the featured applications of X-ray-excited deep nanotheranostics in CT imaging-guided diverse cancer diagnosis, XEOL imagingmonitored drug release, and efficient treatment of multidrug resistant and hypoxic tumors, all of which will be discussed in the following sub-sections."
    }, {
      "heading" : "4.1. Featured Biomedical Applications of CT Imaging",
      "text" : "CT imaging has diverse applications in diagnosis of cancerrelated diseases with the use of “smart” nanomaterials. The representative applications of CT imaging for detection of lymph nodes, tumor hypoxia, and osteosarcoma are talked about below."
    }, {
      "heading" : "4.1.1. CT Imaging of Lymph Nodes",
      "text" : "Lymph nodes (LNs) are the first site of cancer metastases, so LNs around the primary tumor are often removed to prevent the dissemination of cancer cells.[204] However, the enucleation procedures are difficult because the LNs and their linked lymphatic vessels (LVs) are too small to be identified, suggesting a need for advanced molecular imaging techniques. Ishimura and co-workers designed silica-coated gold nanoparticle (Au@SiO2) clusters for contrast-enhanced CT imaging of LNs and LVs.[205] By intradermal injection of Au@SiO2 nanoparticles into the left paws of mice (Figure 15a), the obtained CT maximum intensity projection (MIP) image provided clear vision of LVs in the medial side of the mouse arm (Figure 15b). Moreover, the cervical LNs were visualized in axial CT images (Figure 15c). The Au@SiO2 nanoparticle-enhanced CT imaging could offer accurate anatomical information on the location of LNs/LVs,\nAdv. Mater. 2019, 1806381\nTable 3. Summary of the emergent X-ray-excited synchronous/synergistic therapies and their proposed mechanisms of action.\nTypes Working mechanisms Ref.\nRT/chemotherapy X-ray breaks the DNA strands to release\ndrugs from nanoparticles.\n[49]\nX-ray induces the decomposition\nof nanocapsules to break low energy bonds\n(e.g., diselenide, disulfide, peroxide, etc.)\nand release encapsulated drugs.\n[50,161,162]\nX-ray controls the activation of nontoxic\nprodrug (e.g., IQ-FdUrd, etc.) into toxic one\n(e.g., 5-FdUrd, etc.) via radiolytic reduction.\n[163]\nRT/gas therapy X-ray causes the low energy bond\n(e.g., S-N, etc.) scission within the gas donor\ngroup (e.g., S-nitrosothiol, etc.) to release\ngasotransmitters (e.g., NO, etc.)\nfor radiosensitization.\n[179]\nThe radioluminescence emission\nof scintillators (e.g., LiLuF4:Ce, etc.) upon\nX-ray excitation can activate the gas donors\n(e.g., RBS, etc.) to release gasotransmitters\n(e.g., NO, etc.).\n[180]\nRT/PDT Nanoscintillators (e.g., SrAl2O4:Eu, ZnS:Cu/\nCO, etc.) convert X-ray into UV–vis\nluminescence to activate PSs (e.g., MC540,\nTBrRh123, etc.) for ROS generation.\n[134,146]\nX-ray directly activates inorganic semiconduc-\ntors (e.g., TiO2, etc.) to generate ROS.\n[188]\nRT/immunotherapy X-ray elicits systematic immune response and\nabscopal effect to indirectly increase T cell\ninfiltration and enhance antitumor activity.\n[53,203]\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1806381 (19 of 32)\nwhich may be beneficial for preoperative diagnosis of cancer metastases. Considering the overexpression of human epidermal growth factor receptor 2 (HER-2) in breast cancer, Huo et al. prepared W18O49 NPs conjugated with HER-2 antibody (WOHA) for contrast-enhanced CT imaging of metastatic LNs.[115] The corresponding CT images (Figure 15d,e) showed that the HER-2 overexpressing metastatic LNs were visualized in vivo with the targeting WOHA compared to the W18O49 NP without HER-2 antibody conjugation. The authors further used the accurate localization of HER-2 metastatic LNs as guidance for the photothermal ablation."
    }, {
      "heading" : "4.1.2. CT Imaging of Tumor Hypoxia",
      "text" : "Tumor hypoxia, a salient feature of solid tumors, is associated with invasion and metastasis.[206] Additionally, hypoxic tumors exhibit strong resistance to chemotherapy, PDT, and RT.[207] Therefore, determining the degree of tumor hypoxia by means of noninvasive molecular imaging approaches is important for predicting the biological behavior and treatment response of cancer.[208,209] Although MRI, positron emission tomography (PET) imaging, and optical imaging have been developed for assessing tumor hypoxia,[210–212] these imaging methods have some limitations. For instance, MRI diagnosis takes a long period to acquire high-resolution images, and PET imaging is limited by the low contrast ratio, and tumors typically need an uptake period of 2–3 h before PET imaging.[213] The low tissue penetration makes optical imaging difficult to detect deep tumor hypoxia. With low cost, deep penetration, and superior\nspatial/temporal resolution, CT imaging may possess advantages in visualization and assessment of tumor hypoxia.\nShi et al. developed a hypoxia-sensitive CT imaging probe for identifying the different levels of hypoxia in two xenografts (BxPC-3 and HT-1080).[214] This nanoprobe (Au@BSA-NHA, Figure 16a) consisted of bovine serum albumin (BSA)-coated Au nanoparticles and a hypoxia-sensitive nitroimidazole (NHA) moiety. The nitro group of NHA could be reduced by nitroreductase (NTR) under hypoxic condition. The representative CT images of both BxPC-3- and HT-1080-tumor-bearing mice (Figure 16b,c) showed that the intravenous injection of Au@ BSA-NHA resulted in much stronger CT contrast in tumor sites than that of Au@BSA, which indicated that the conjugated NHA moiety was responsible for promoting the tumor accumulation of Au@BSA and the well-designed Au@BSA-NHA acted as a targeted CT contrast agent for sensing tumor hypoxia in vivo. Moreover, the quantitative analysis of the temporal CT value changes in tumor regions clearly reflected the intratumoral-hypoxia imaging behavior of Au@BSA-NHA and allowed visualization of intratumoral hypoxic level (Figure 16d–f). The authors also performed the immunostaining analysis of the hypoxic markers (hypoxia-inducible-1 alpha (HIF-1α) and vascular endothelial growth factor (VEGF)) to estimate the tumor hypoxia level, and the results were consistent with the CT imaging detection. Therefore, Au@BSA-NHA has potential to be used for the qualitative monitoring of the hypoxic TME with CT enhancement as well as the quantitative evaluation of the hypoxic level by the degree of CT contrast enhancement, which will contribute to the personalized estimation of tumor hypoxia noninvasively and conveniently.\nAdv. Mater. 2019, 1806381\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1806381 (20 of 32)"
    }, {
      "heading" : "4.1.3. Spectral CT Diagnosis of Osteosarcoma",
      "text" : "Owing to the high imaging sensitivity to bones, CT imaging has been extensively used for the diagnosis of osteosarcoma, the most common primary bone cancer.[215,216] However, conventional CT imaging faces difficulty in differentiating between bones and areas of osteosarcoma when CAs are administered because the attenuation in bone is very similar to that generated by CAs. Fortunately, the newly explored gemstone spectral CT (GSCT) can overcome this Achilles’ heel of conventional CT by using the advanced single-source dual-energy imaging technique.[217] GSCT images are usually captured through fast switch (within 50 µs) of low energy (≈80 kVp) and high energy (≈170 kVp),[218] which may apply to the differentiation of materials with similar X-ray attenuation. Meanwhile, the monochromatic energy images in GSCT have improved signal-to-noise ratio and reduced metal/beamhardening artifacts, which offers greater diagnostic accuracy for osteosarcoma. As the clinical used iohexol is unable to be differentiated from bones in high-energy GSCT images, the qualified GSCT CAs remain to be explored for the accurate diagnosis of osteosarcoma.\nRecently, Zhang and co-workers reported the use of Lubased UCNPs (NaLuF4:Yb/Er) nanoparticles as GSCT CAs for the detection of osteosarcoma (Figure 17a).[219] The decrease speed of X-ray attenuation of iohexol and CaCl2 increase with higher monochromatic energy (40–140 keV), while the X-ray\nattenuation of Lu-based UCNPs decreased slightly, which demonstrated the huge difference of their X-ray attenuation especially at the high energy level. Moreover, the material decomposition (an important parameter in GSCT scanning) images effectively distinguished Lu-based UCNPs from iohexol and bone (Figure 17b). The in vivo monochromatic GSGT images (Figure 17c,d) clearly showed that Lu-based UCNPs successfully differentiated the osteosarcoma from surrounding bones, demonstrating the superiority of Lu-based UCNPs over iohexol for the detection of osteosarcoma with GSCT. The Lu-based UCNPs may hold great potential for the accurate diagnosis of other skeletal system diseases under the contrast-enhanced GSCT imaging guidance, but their biocompatibility and excretion still need to be evaluated and observed for a long period."
    }, {
      "heading" : "4.2. Featured Biomedical Applications of XEOL Imaging",
      "text" : "As mentioned, XEOL imaging with its deep tissue penetration and extremely low tissue autofluorescence,[220] may promise significant value for use in monitoring the drug release at deep sites. XEOL imaging requires X-ray-to-light conversion via scintillating materials; however, there is another XEOL imaging approach, called X-ray fluorescence (XRF) imaging. XRF is based on the released fluorescence energy when the outer sphere electrons of an element drops to lower energy atomic orbitals upon excitation by X-ray radiation.[221] The resulting\nAdv. Mater. 2019, 1806381\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1806381 (21 of 32)\ncharacteristic fluorescence emission lines in unoccupied regions offer great possibilities for application in quantitative multichannel biological imaging."
    }, {
      "heading" : "4.2.1. Multichannel Biological XRF Imaging",
      "text" : "In 2016, Serpell et al. engineered single-walled carbon nanotubes (SWCNTs) as contrast agents for multichannel biological XRF imaging.[222] The SWCNTs were filled with a wide range of biologically absent elements (e.g., Pb, Ba, Kr, etc.) and modified with targeting ligands for probing cellular organelles through multiplexed XRF mapping (Figure 18a). In the SWCNTs-treated cells, the contrast element signals allowed the authors to map cellular architectures (Figure 18b–e). The authors conjugated RGD peptides to SWCNTs containing either Pb, Ba or Kr as the filling element. All three derivatives bound to cell surface integrin in HeLa cells. SWCNTs were also conjugated with SV40 and IL-1a peptides, with the same filling elements. In both cases, the nanotubes localized to the nucleus of the cell. It can be concluded that suitably engineered SWCNTs can generate high-resolution imaging of specific organelles by using multichannel XRF mapping; however, the performance of XRF imaging for in vivo systems has yet to be tested."
    }, {
      "heading" : "4.2.2. XEOL Imaging-Monitored Drug Release",
      "text" : "When the radioluminescence intensity of scintillating nanomaterials has some relationship with the loaded drug amount, the subsequent drug release can be monitored by XEOL imaging.\nChen et al. conducted a “proof-of-concept” study to demonstrate that XEOL imaging can be used to monitor drug release. They synthesized Gd2O2S:Tb-based radioluminescent capsules as a DOX nanocarrier and release monitor.[75] To the surface of the Gd2O2S:Tb capsules, a pH-responsive polyelectrolyte (PSS/PAH) multilayer was added for the in vitro pH-triggered release of DOX (Figure 19a,b). Due to the spectral overlap between the broad absorption of DOX and the XEOL emission of Gd2O2S:Tb (Figure 19c), the released DOX amount was estimated using the radioluminescence intensity ratio at 544 and 620 nm (Figure 19d). Of note, the XEOL imaging offers several advantages over traditional optimal imaging methods in noninvasive monitoring of drug release, such as large tissue penetration, extremely autofluorescence, and high spatial resolution.\nLater, Moore et al. used XEOL imaging to monitor the release of a photoactive drug (protoporphyrin IX, PpIX) instead of DOX (Figure 20a).[139] The XEOL nanoparticles (Gd2O2S:Eu) were coated with poly(glycolide)-poly(ethylene glycol) (denoted as XGP) to encapsulate PpIX. Due to the partial overlap between the absorption spectrum of PpIX and the XEOL emission spectrum of XGP (Figure 20b), the loaded PpIX could attenuate the radioluminescence emission of XGP. It was observed that the radioluminescence peak of XGP at 625 nm showed a distinct attenuation with increased loading of PpIX, while the radioluminescence peak at 700 nm was largely unaffected (Figure 20c). Subsequently, the radioluminescence peak ratio at 625 nm/700 nm of XGP was used as an internal reference to measure the PpIX loading amount regardless of X-ray doses. The gradual PpIX release from XGP was monitored by analyzing the increased radioluminescence peak ratio at 625 nm/700 nm (Figure 20d). The uptake and release kinetics\nAdv. Mater. 2019, 1806381\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1806381 (22 of 32)\nAdv. Mater. 2019, 1806381\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1806381 (23 of 32)\nAdv. Mater. 2019, 1806381\nof XGP were assessed in glioblastoma U-138MG cells. The XGP-internalized U-138MG cells demonstrated the maximum radioluminescence intensity at 24 h (Figure 20e), which indicated the highest cellular uptake of XGP was at this time point. Figure 20f–h showed that the intracellular PpIX release from XGP led to the enhancement of the radioluminescence intensity of U-138MG cellular pellets, which confirmed the feasibility of in vitro XEOL imaging-monitored drug release. This study paves the road for the establishment of a noninvasive XEOL imaging approach to track drug delivery and quantitatively monitor drug release in cells."
    }, {
      "heading" : "4.3. Featured Biomedical Applications of X-Ray-Excited Synchronous/Synergistic Therapy",
      "text" : "Multidrug resistance (MDR) and tumor hypoxia are two major obstacles for successful cancer treatment. The repeated use of anticancer drugs can cause tumors to develop MDR, which usually results in the failure of chemotherapy.[223] On the other\nhand, tumor hypoxia is responsible for the ineffectiveness of the oxygen-dependent therapeutic modalities, such as PDT and RT.[224–226] Since monotherapy is unlikely to overcome tumor MDR and hypoxia, multimodal synchronous/synergistic therapy based on the concurrent use of two or more therapeutic modalities is better suited for treating multidrug resistant or hypoxic tumors. In this section, we will overview the emergent literatures for targeting tumor MDR and tumor hypoxia with X-ray-excited synchronous/synergistic therapy."
    }, {
      "heading" : "4.3.1. Reversing Tumor Multidrug Resistance",
      "text" : "The overexpression of P-glycoprotein (P-gp) pumps in cancer cells is capable of reducing intracellular concentration of chemotherapeutics by drug efflux.[227,228] Therefore, strategies that downregulate P-gp expression or inhibit P-gp activity can overcome MDR and enhance chemotherapeutic efficacy. Compared to free drugs, the drug nanocarriers can bypass the efflux of P-gp to deliver drugs into MDR cancer cells for improved cell\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1806381 (24 of 32)\nAdv. Mater. 2019, 1806381\nkilling.[229–231] For example, the direct delivery of DNA alkylating agents or topoisomerase inhibitors to the cell nucleus by nanocarriers can circumvent P-gp efflux and also bring the chemotherapeutic agent closer to its intended target.[232] Moreover, this strategy can be applied to radiosensitizers in combination with high-energy X-rays for synergistic chemo-/radiotherapeutic effects on reversing MDR. This technique is called “intranuclear radiosensitization” aimed at directly damaging the DNA of MDR cells through the intranuclear chemodrug-sensitized radiation enhancement effects.\nTo study the application of “intranuclear radiosensitization” for overcoming MDR, we designed a nuclear-targeting nanocarrier based on sub-50 nm rattle-structured upconversion core/mesoporous silica nanostructure (RUMSNs).[233] The Gd-doped upconversion core (NaYF4:Yb/Er/Tm/Gd) provided MR/UCL dual modal-imaging guidance, while the intermediate cavity and mesoporous channels of silica shell were used to encapsulate the radiosensitizing drug Mitomycin C (MMC). Following surface conjugation with a nuclear localization signal (NLS) TAT peptide,[234,235] the as-synthesized RUMSNs-TAT delivered the MMC into the nucleus of MDR cells (Figure 21a). Figure 21b showed that RUMSNs-TAT-MMC killed more MCF-7/ADR cells than free MMC or RUMSNs-MMC under the assistance of X-ray irradiation, which indicated that the intranuclear drug delivery produced more significant radiosensitizing effects than extracellular drug delivery or intracytoplasmic drug delivery. By comparison with the extranuclear radiosensitization (MMC + RT) and intracytoplasmic radiosensitization (RUMSNs-MMC + RT), the intranuclear radiosensitization (RUMSNs-TAT-MMC + RT) gave rise to much stronger MDR reversal effects for more remarkably reducing ATP level and P-gp expression in MCF-7/MDR cells (Figure 21c,d).\nThe treatment of RUMSNs-TAT-MMC + RT even suppressed and regressed the growth of MCF-7/MDR tumors in vivo (Figure 21e), which demonstrated that the intranuclear X-rayexcited synchronous/synergistic RT/chemotherapy would be useful for targeting MDR cancers."
    }, {
      "heading" : "4.3.2. Overcoming Tumor Hypoxia",
      "text" : "Most organic PSs (e.g., porphyrin, chlorine, phthalocyanine, etc.) upon light activation participate in a typical photochemical II reaction where oxygen molecules are involved in the generation of cytotoxic 1O2.[236,237] This type II PDT process relies on the participation of oxygen and can only take effect in highoxygen environment.[238] However, some inorganic PSs (e.g., TiO2, CdSe, ZnO, etc.) can initiate a typical photochemical I reaction process with the involvement of H2O instead of O2 to generate •OH.[239,240] Therefore, the oxygen-independent type I PDT may be useful for the treatment of hypoxic tumors in lowoxygen environment. With the use of SCNPs, inorganic PSs can be indirectly activated by X-ray to generate •OH for type I PDT together with RT. Such a unique approach of X-ray-excited synchronous/synergistic type I PDT/RT not only overcomes the tissue penetration limitation of PDT, but also avoids the oxygen dependence of PDT/RT.\nShi et al. fabricated a SCNP/inorganic PS hybrid nanostructure (LiYF4:Ce@SiO2@ZnO, SZNP, Figure 22a).[133] The LiYF4:Ce core served as a SCNP to convert X-ray into UV–vis luminescence, which could activate the ZnO semiconductor to produce •OH derived from the reaction between the as-formed electron–hole (e−-h+) pairs and water (Figure 22b). The spectral overlap between the emission of LiYF4:Ce and absorption of ZnO\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1806381 (25 of 32)\nAdv. Mater. 2019, 1806381\n(Figure 22c) facilitated the luminescence energy transfer for •OH generation, as confirmed by the methylene blue (MB) bleaching result (Figure 22d). The combination of SZNP and RT increased ROS yield by two fold in HeLa cells incubated in hypoxic conditions (2% O2) compared to SZNP or RT alone (Figure 22e), which suggested that such a typical X-ray-excited type I PDT process could minimize the oxygen dependency. While RT alone seemingly had no influence on cell viability in hypoxic HeLa cells, the treatment of SZNP + RT led to 30% reduction in cell viability at 50 µg/mL SZNP and 6 Gy of X-ray irradiation (Figure 22f). While this study demonstrates that type I PDT and RT can induce cell death in hypoxic conditions, the X-ray-excited synchronous therapeutic efficacy needs to be further improved.\nIn order to further enhance the X-ray-excited RT/PDT efficacy on treating hypoxic tumors, Bu and co-workers combined chemotherapy with RT/PDT for the establishment of trimodal synchronous/synergistic RT/PDT/chemotherapy through the design of an X-ray-responsive ROS/drug release system.[241] In their LiLuF4:Ce@SiO2@Ag3PO4@Pt(IV) nanostructure (LAPNP, Figure 23a), the LiLuF4:Ce nanoscintillator core was responsible for converting X-ray radiation into UV radioluminescence to activate the Ag3PO4 nanosemiconductor for •OH generation (Figure 23b,c). Designed at increasing the •OH yield of X-ray-excited RT/PDT, the cisplatin prodrug (Pt(IV)) was attached to the surface of LiLuF4:Ce@SiO2@Ag3PO4 (LAPN) to behave as a sacrificial electron acceptor for separating more electrons and holes in Ag3PO4. As such, LAPNP caused faster\ndecay in RhB absorption than LAPN upon X-ray irradiation, which accounted for the higher X-ray-responsive •OH yield (Figure 23d,e). Moreover, X-ray activated the nontoxic prodrug (Pt(IV)) into toxic cisplatin via the acceptance of electrons (Figure 23f), which simultaneously provided chemotherapy for enhancing the •OH-mediated DNA damage. Since oxygen was not required for •OH/cisplatin production, the whole process of trimodal synchronous/synergistic RT/PDT/chemotherapy (LAPNP plus X-ray) relied little on oxygen, inducing apoptosis in both normoxic (21% O2) and hypoxic (2% O2) HeLa cells (Figure 23g,h). Besides, LAPNP had higher hypoxic cell death than LAPN upon X-ray irradiation, suggesting that Pt(IV) helped to amplify the effect of X-ray-excited RT/PDT on overcoming tumor hypoxia. When evaluated in vivo, the treatment of LAPNP + X-ray led to the inhibition and regression of HeLa tumor growth. In contrast, the tumor growth progressed with the other treatments (Figure 23i). This study is the first report where X-ray radiation was used to simultaneously activate three kinds of treatments with no dependence on oxygen, which highlights the potential of X-ray for optimized treatment of deep-seated hypoxic tumors."
    }, {
      "heading" : "5. Conclusions and Outlook",
      "text" : "The significant advances in nanotechnology have catalyzed new innovations for cancer theranostics. In the past decade, we have\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1806381 (26 of 32)\nAdv. Mater. 2019, 1806381\nwitnessed emergent contributions of nanotechnology to deep cancer theranostics by exploiting X-ray as a highly penetrating energy source for targeting deep-seated tumors. The cross-disciplinary researches of chemistry, physics, biology, and medicine have greatly shifted the X-ray-excited imaging/treatment paradigms from traditional CT/RT to XEOL imaging and multimodal synchronous/synergistic RT-based therapy (Table 4), which remarkably improves the overall theranostic effectiveness of deep-seated diseases. Given the precise control that X-ray radiation offers, it has enabled researchers to maximize theranostic efficacy, while minimizing potential adverse effects.\nWe began by discussing the principles and characteristics of X-rays from conventional CT and RT, with a detailed introduction to the construction of high-Z element containing nanomaterials and scintillating nanomaterials for contrastenhanced CT imaging and high spatial XEOL imaging, respectively. We proceeded to discuss the use of nanomaterials for X-ray-excited multimodal synchronous/synergistic therapy (RT/chemotherapy, RT/gas therapy, RT/PDT, RT/immunotherapy).\nDistinct from other RT-related combination therapy, these four types of multimodal therapy are excited by a single X-ray source so the concern about tissue penetration can be neglected. More importantly, X-ray can activate the simultaneous use of RT and other treatments to further improve the synergistic therapeutic effect, and the on-demand deep cancer therapy can be realized through the precise control of X-ray radiation doses. Subsequently, we highlighted the featured biomedical applications, such as CT imaging-mediated detection of lymph nodes/ tumor hypoxia/osteosarcoma, XEOL imaging-monitored drug release, and RT-based synchronous/synergistic treatments to overcome tumor MDR/hypoxia. Despite the prominent breakthroughs made in this field, a number of critical issues remain to be addressed before these X-ray-excited deep theranostic techniques can transition from bench to bedside.\nFor CT imaging, the design of high-performance CAs for accurate differentiation of lesion areas from the surrounding normal tissues is still a daunting task. Especially in cancer diagnosis, the long-circulating surface-engineered CAs composed of\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1806381 (27 of 32)\nAdv. Mater. 2019, 1806381\nlarge quantities of heavy atoms and conjugated with targeting ligands are highly attractive for targeted contrast-enhanced CT imaging of deep-seated tumors. Besides, it is urgently needed to establish a standard “gold protocol” to grade the performance of CAs. Currently the contrast effect of CAs is evaluated in the terms of HU value, which is not a general reference and varies by the concentration of CAs. Therefore, the search for a concentration-independent parameter (like r1 or r2 relaxivity for MRI) is conducive to accurately estimating the contrast performance of various kinds of CT CAs.\nFor XEOL imaging, the radioluminescence intensity of scintillating nanomaterials remains weak because of relatively low X-ray-to-light conversion efficiency, which negatively impacts sensitivity and resolution. The performance of scintillating nanomaterials is usually determined by their composition, crystalline phase and surface property. The high Z elementcontained host matrix is a prerequisite for enhanced radioluminescence due to its great X-ray stopping power. Besides, the increased doping concentration of high-Z elements (as activators) without self-quenching is supposed to shorten the excitation migration pathway, which leads to remarkable enhancement of X-ray-induced luminescence intensity of scintillating nanomaterials. Usually scintillating nanomaterials with hexagonal crystals exhibit much higher radioluminescence intensity than those with cubic crystals. Moreover, the fabrication of core/shell-structured scintillating nanomaterials\nby coating the core nanoparticle with a layer\nimmunity as in situ vaccines. As with most treatment applications, it will be beneficial to incorporate an imaging component into the nanocarriers to monitor treatment response.\nWhile a lot of these technologies introduced in this paper hold great promise, the large majority of the studies were performed in test tubes or in cells. It is critical that these platforms be evaluated in appropriate in vivo systems. The evaluation of X-ray-excited theranostic effectiveness should be performed on the deep-seated orthotopic tumor models rather than on subcutaneous tumor models to understand the treatment efficacy given the depth penetrance. In addition, the more clinically relevant patient-derived xenograft (PDX) tumors can be inoculated inside larger animals (e.g., rabbits, etc.).\nAs with any ionizing radiation source, there is potential for radiation damage to normal tissues. As such, the related X-ray instruments should be remarkably improved by anchoring the advanced deep penetrating imaging devices to provide precise guidance for accurately delivering the X-ray radiation to the lesion site. Growing concerns about the toxicity of X-ray-excited theranostics may also arise from the widespread use of high-Z element-containing inorganic nanomaterials. Numerous in vivo toxicity studies have found little adverse effects on the health status of animals at the therapeutic dose of nanomaterials. Generally speaking, the negligible leakage of heavy metal ions from the crystalline host matrix substantially decreases the toxicity of inorganic nanomaterials, and the proper surface\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1806381 (28 of 32)\nAdv. Mater. 2019, 1806381\nmodification further improves the biocompatibility of inorganic nanomaterials, both of which can relieve the biosafety concern of the X-ray-excited theranostic technology to some extent. Nevertheless, given the increasing complexity of the nanomaterials and their associated treatments (e.g., chemotherapy, PDT, PTT, etc.), it is crucial that these therapeutic studies be accompanied with comprehensive histological toxicity studies, both acute and long-term, prior to clinical trial.\nInorganic nanomaterials are featured with some distinct merits that most organic nanomaterials cannot offer, such as uniform morphology, controllable size, high dispersity, great stability, and easy multifunctionalization. Unfortunately, only few inorganic nanomaterials have been tested in human because several improvements are still needed. First, the potential toxicity of inorganic nanomaterials should be systemically evaluated and thoroughly solved to ensure high biocompatibility with advanced toxicological assessment and synthetic chemistry methods. Second, inorganic nanomaterials should be endowed with endogenous stimuli-responsive biodegradability to avoid longtime body retention and realize complete in vivo clearance. Third, the surface of inorganic nanomaterials should be\n“camouflaged” to achieve prolonged blood\nResearch Program (IRP) of the NIBIB, NIH, the Youth Innovation Promotion Association of Chinese Academy of Sciences (2016269), and the National Key Research & Development Program (2016YFC1400600 and 2018YFD0800300).\nConflict of Interest The authors declare no conflict of interest.\nKeywords deep theranostics, nanomaterials, nanotechnology, synchronous/ synergistic therapy, X-ray radiation\nReceived: October 2, 2018 Revised: November 26, 2018\nPublished online:\n[1] R. L. Siegel, K. D. Miller, A. Jemal, Ca-Cancer J. Clin. 2018, 68, 7. [2] G. Pillai, J. Pharm. Sci. Pharmacol. 2014, 1, 1.\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1806381 (29 of 32)\nAdv. Mater. 2019, 1806381\n[3] T. Lammers, F. Kiessling, W. E. Hennink, G. Storm, J. Controlled Release 2012, 161, 175. [4] H. Maeda, H. Nakamura, J. Fang, Adv. Drug Delivery Rev. 2013, 65, 71. [5] P. M. Mitrasinovic, M. L. Mihajlovic, Curr. Radiopharm. 2008, 1, 22. [6] K. Haume, S. Rosa, S. Grellet, M. A. Śmiałek, K. T. Butterworth,\nA. V. Solov’yov, K. M. Prise, J. Golding, N. J. Mason, Cancer Nanotechnol. 2016, 7, 8. [7] W. P. Hogle, Semin. Oncol. Nurs. 2006, 22, 212. [8] A. Z. Wang, J. E. Tepper, J. Clin. Oncol. 2014, 32, 2879. [9] H. Shirato, Q.-T. Le, K. Kobashi, A. Prayongrat, S. Takao,\nS. Shimizu, A. Giaccia, L. Xing, K. Umegaki, J. Radit. Res. 2018, 59, i2. [10] Y. Xue, W. R. Wilcox, Cancer Biol. Med. 2016, 13, 12. [11] S. H. Shin, A. M. Bode, Z. Dong, npj Precis. Oncol. 2017, 1, 12. [12] S. Rockwell, I. T. Dobrucki, E. Y. Kim, S. T. Marrison, V. T. Vu,\nCurr. Mol. Med. 2009, 9, 442. [13] L. B. Harrison, M. Chadha, R. J. Hill, K. Hu, D. Shasha, Oncologist\n2002, 7, 492. [14] D. J. Carlson, K. M. Yenice, C. G. Orton, Med. Phys. 2011, 38, 6347. [15] C. Bettegowda, L. H. Dang, R. Abrams, D. L. Huso, L. Dillehay,\nI. Cheong, N. Agrawal, S. Borzillary, J. M. McCaffery, E. L. Watson, K. S. Lin, F. Bunz, K. Baidoo, M. G. Pomper, K. W. Kinzler, B. Vogelstein, S. Zhou, Proc. Natl. Acad. Sci. USA 2003, 100, 15083. [16] F. Pajonk, E. Vlashi, W. H. McBride, Stem Cells 2010, 28, 639. [17] A. Malik, M. Sultana, A. Qazi, M. H. Qazi, G. Parveen, S. Waquar, A. B. Ashraf, M. Rasool, Anal. Cell. Pathol. 2016, 2016, 1. [18] P. Wardman, Clin. Oncol. 2007, 19, 397. [19] S. Alcorn, A. Walker, N. Gandhi, A. Narang, A. Wild, R. Hales,\nJ. Herman, D. Song, T. DeWeese, E. Antonarakis, P. Tran, Int. J. Mol. Sci. 2013, 14, 14800. [20] T. Nakae, Y. Uto, M. Tanaka, H. Shibata, E. Nakata, M. Tominaga, H. Maezawa, T. Hashimoto, K. L. Kirk, H. Nagasawa, H. Hori, Bioorg. Med. Chem. 2008, 16, 675. [21] G. Song, Y. Chen, C. Liang, X. Yi, J. Liu, X. Sun, S. Shen, K. Yang, Z. Liu, Adv. Mater. 2016, 28, 7143. [22] G. Song, C. Liang, X. Yi, Q. Zhao, L. Cheng, K. Yang, Z. Liu, Adv. Mater. 2016, 28, 2716. [23] M. De Ridder, D. Verellen, V. Verovski, G. Storme, Nitric Oxide 2008, 19, 164. [24] G. De Preter, C. Deriemaeker, P. Danhier, L. Brisson, T. T. Cao Pham, V. Gregoire, B. F. Jordan, P. Sonveaux, B. Gallez, Mol. Cancer Ther. 2016, 15, 154. [25] P. Wardman, K. Rothkamm, L. K. Folkes, M. Woodcock, P. J. Johnston, Radiat. Res. 2007, 167, 475. [26] C. Jin, L. Bai, H. Wu, F. Tian, G. Guo, Biomaterials 2007, 28, 3724. [27] M. E. Werner, J. A. Copp, S. Karve, N. D. Cummings, R. Sukumar,\nC. Li, M. E. Napier, R. C. Chen, A. D. Cox, A. Z. Wang, ACS Nano 2011, 5, 8990. [28] B. Shen, K. Zhao, S. Ma, D. Yuan, Y. Bai, Chem. - Asian J. 2015, 10, 344. [29] Y. Liu, P. Zhang, F. Li, X. Jin, J. Li, W. Chen, Q. Li, Theranostics 2018, 8, 1824. [30] N. Goswami, Z. Luo, X. Yuan, D. T. Leong, J. Xie, Mater. Horiz. 2017, 4, 817. [31] H. Xing, X. Zheng, Q. Ren, W. Bu, W. Ge, Q. Xiao, S. Zhang, C. Wei, H. Qu, Z. Wang, Y. Hua, L. Zhou, W. Peng, K. Zhao, J. Shi, Sci. Rep. 2013, 3, 1751. [32] X.-D. Zhang, J. Chen, Y. Min, G. B. Park, X. Shen, S.-S. Song, Y.-M. Sun, H. Wang, W. Long, J. Xie, K. Gao, L. Zhang, S. Fan, F. Fan, U. Jeong, Adv. Funct. Mater. 2014, 24, 1718. [33] Y.-S. Yang, R. P. Carney, F. Stellacci, D. J. Irvine, ACS Nano 2014, 8, 8992. [34] Y. Yong, C. Zhang, Z. Gu, J. Du, Z. Guo, X. Dong, J. Xie, G. Zhang, X. Liu, Y. Zhao, ACS Nano 2017, 11, 7164.\n[35] Q. Xie, G. Lan, Y. Zhou, J. Huang, Y. Liang, W. Zheng, X. Fu, C. Fan, T. Chen, Cancer Lett. 2014, 354, 58. [36] G. Song, Y. Chao, Y. Chen, C. Liang, X. Yi, G. Yang, K. Yang, L. Cheng, Q. Zhang, Z. Liu, Adv. Funct. Mater. 2016, 26, 8243. [37] S. J. McMahon, W. B. Hyland, M. F. Muir, J. A. Coulter, S. Jain, K. T. Butterworth, G. Schettino, G. R. Dickson, A. R. Hounsell, J. M. O’Sullivan, K. M. Prise, D. G. Hirst, F. J. Currell, Sci. Rep. 2011, 1, 18. [38] I. J. Das, F. M. Kahn, Med. Phys. 1989, 16, 367. [39] K. Kobayashi, N. Usami, E. Porcel, S. Lacombe, C. Le Sech, Mutat.\nRes., Rev. Mutat. Res. 2010, 704, 123. [40] M. Falk, Ann. Transl. Med. 2017, 5, 18. [41] R. I. Berbeco, W. Ngwa, G. M. Makrigiorgos, Int. J. Radiat. Oncol.,\nBiol., Phys. 2011, 81, 270. [42] J. Schuemann, R. Berbeco, D. B. Chithrani, S. H. Cho, R. Kumar,\nS. J. McMahon, S. Sridhar, S. Krishnan, Int. J. Radiat. Oncol., Biol., Phys. 2016, 94, 189. [43] Y. Yang, Y. Chao, J. Liu, Z. Dong, W. He, R. Zhang, K. Yang, M. Chen, Z. Liu, NPG Asia Mater. 2017, 9, e344. [44] M.-h. Yao, M. Ma, Y. Chen, X.-q. Jia, G. Xu, H.-x. Xu, H.-r. Chen, R. Wu, Biomaterials 2014, 35, 8197. [45] E. Spyratou, M. Makropoulou, E. A. Mourelatou, C. Demetzos, Cancer Lett. 2012, 327, 111. [46] A. R. Montazerabadi, A. Sazgarnia, M. H. Bahreyni-Toosi, A. Ahmadi, A. Aledavood, J. Photochem. Photobiol., B 2012, 109, 42. [47] W. Cao, Y. Gu, M. Meineck, H. Xu, Chem. - Asian J. 2014, 9, 48. [48] G. D. Wang, H. T. Nguyen, H. Chen, P. B. Cox, L. Wang, K. Nagata, Z. Hao, A. Wang, Z. Li, J. Xie, Theranostics 2016, 6, 2295. [49] Z. B. Starkewolf, L. Miyachi, J. Wong, T. Guo, Chem. Commun. 2013, 49, 2545. [50] N. Ma, H. Xu, L. An, J. Li, Z. Sun, X. Zhang, Langmuir 2011, 27, 5874. [51] A.-L. Bulin, C. Truillet, R. Chouikrat, F. Lux, C. Frochot, D. Amans, G. Ledoux, O. Tillement, P. Perriat, M. Barberi-Heyob, C. Dujardin, J. Phys. Chem. C 2013, 117, 21583. [52] S. N. Seyedin, J. E. Schoenhals, D. A. Lee, M. A. Cortez, X. Wang, S. Niknam, C. Tang, D. S. Hong, A. Naing, P. Sharma, J. P. Allison, J. Y. Chang, D. R. Gomez, J. V. Heymach, R. U. Komaki, L. J. Cooper, J. W. Welsh, Immunotherapy 2015, 7, 967. [53] Y. Min, K. C. Roche, S. Tian, M. J. Eblan, K. P. McKinnon, J. M. Caster, S. Chai, L. E. Herring, L. Zhang, T. Zhang, J. M. DeSimone, J. E. Tepper, B. G. Vincent, J. S. Serody, A. Z. Wang, Nat. Nanotechnol. 2017, 12, 877. [54] S. C. Formenti, S. Demaria, JNCI, J. Natl. Cancer Inst. 2013, 105, 256. [55] S. Kunjachan, J. Ehling, G. Storm, F. Kiessling, T. Lammers, Chem. Rev. 2015, 115, 10907. [56] E. Terreno, F. Uggeri, S. Aime, J. Controlled Release 2012, 161, 328. [57] S. M. Janib, A. S. Moses, J. A. MacKay, Adv. Drug Delivery Rev.\n2010, 62, 1052. [58] M. F. Kircher, H. Hricak, S. M. Larson, Mol. Oncol. 2012, 6, 182. [59] A. R. Pantel, D. A. Mankoff, Cancer Lett. 2017, 387, 25. [60] H. Hricak, Radiology 2011, 259, 633. [61] M. Bourin, P. Jolliet, F. Ballereau, Clin. Pharmacokinet. 1997, 32,\n180. [62] M. F. Kircher, J. K. Willmann, Radiology 2012, 263, 633. [63] F. Hyafil, J.-C. Cornily, J. E. Feig, R. Gordon, E. Vucic,\nV. Amirbekian, E. A. Fisher, V. Fuster, L. J. Feldman, Z. A. Fayad, Nat. Med. 2007, 13, 636. [64] L. W. Goldman, J. Nucl. Med. Technol. 2008, 36, 57. [65] J. K. Willmann, N. van Bruggen, L. M. Dinkelborg, S. S. Gambhir,\nNat. Rev. Drug Discovery 2008, 7, 591. [66] S.-B. Yu, A. D. Watson, Chem. Rev. 1999, 99, 2353.\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1806381 (30 of 32)\nAdv. Mater. 2019, 1806381\n[67] D. P. Cormode, P. C. Naha, Z. A. Fayad, Contrast Media Mol. Imaging 2014, 9, 37. [68] D. P. Cormode, Z. A. Fayad, Imaging Med. 2011, 3, 263. [69] Y. Liu, K. Ai, L. Lu, Acc. Chem. Res. 2012, 45, 1817. [70] C. W. E. v. Eijk, Phys. Med. Biol. 2002, 47, R85. [71] G. Blasse, Chem. Mater. 1994, 6, 1465. [72] Y. V. Yermolayeva, T. I. Korshikova, A. V. Tolmachev, R. P. Yavetskiy,\nRadiat. Meas. 2011, 46, 551. [73] S. Shi, M. Hossu, R. Hall, W. Chen, J. Mater. Chem. 2012, 22,\n23461. [74] T. Paunesku, S. Vogt, J. Maser, B. Lai, G. Woloschak, J. Cell.\nBiochem. 2006, 99, 1489. [75] H. Chen, T. Moore, B. Qi, D. C. Colvin, E. K. Jelen, D. A. Hitchcock,\nJ. He, O. T. Mefford, J. C. Gore, F. Alexis, J. N. Anker, ACS Nano 2013, 7, 1178. [76] A. de Vries, E. Custers, J. Lub, S. van den Bosch, K. Nicolay, H. Grüll, Biomaterials 2010, 31, 6537. [77] H. Lusic, M. W. Grinstaff, Chem. Rev. 2013, 113, 1641. [78] D. Ni, W. Bu, S. Zhang, X. Zheng, M. Li, H. Xing, Q. Xiao, Y. Liu,\nY. Hua, L. Zhou, W. Peng, K. Zhao, J. Shi, Adv. Funct. Mater. 2014, 24, 6613. [79] C. Haller, I. Hizoh, Invest. Radiol. 2004, 39, 149. [80] W. Cai, X. Chen, Small 2007, 3, 1840. [81] H. Aviv, S. Bartling, F. Kieslling, S. Margel, Biomaterials 2009, 30,\n5610. [82] K. E. deKrafft, Z. Xie, G. Cao, S. Tran, L. Ma, O. Z. Zhou, W. Lin,\nAngew. Chem., Int. Ed. 2009, 48, 9901. [83] K. B. Ghaghada, C. T. Badea, L. Karumbaiah, N. Fettig,\nR. V. Bellamkonda, G. A. Johnson, A. Annapragada, Acad. Radiol. 2011, 18, 20. [84] J. G. Gelovani, C. T. Badea, K. K. Athreya, G. Espinosa, D. Clark, A. P. Ghafoori, Y. Li, D. G. Kirsch, G. A. Johnson, A. Annapragada, K. B. Ghaghada, PLoS One 2012, 7, e34496. [85] Y. Zou, Y. Wei, G. Wang, F. Meng, M. Gao, G. Storm, Z. Zhong, Adv. Mater. 2017, 29, 1603997. [86] J. Xu, M. Yu, P. Carter, E. Hernandez, A. Dang, P. Kapur, J.-T. Hsieh, J. Zheng, Angew. Chem., Int. Ed. 2017, 56, 13356. [87] J. F. Hainfeld, D. N. Slatkin, T. M. Focella, H. M. Smilowitz, Br. J. Radiol. 2006, 79, 248. [88] D. Kim, S. Park, J. H. Lee, Y. Y. Jeong, S. Jon, J. Am. Chem. Soc. 2007, 129, 7661. [89] J. Li, A. Chaudhary, S. J. Chmura, C. Pelizzari, T. Rajh, C. Wietholt, M. Kurtoglu, B. Aydogan, Phys. Med. Biol. 2010, 55, 4389. [90] T. Reuveni, M. Motiei, Z. Romman, A. Popovtzer, R. Popovtzer, Int. J. Nanomed. 2011, 6, 2859. [91] O. Rabin, J. Manuel Perez, J. Grimm, G. Wojtkiewicz, R. Weissleder, Nat. Mater. 2006, 5, 118. [92] K. Ai, Y. Liu, J. Liu, Q. Yuan, Y. He, L. Lu, Adv. Mater. 2011, 23, 4886. [93] N. Lee, H. R. Cho, M. H. Oh, S. H. Lee, K. Kim, B. H. Kim, K. Shin, T.-Y. Ahn, J. W. Choi, Y.-W. Kim, S. H. Choi, T. Hyeon, J. Am. Chem. Soc. 2012, 134, 10309. [94] J. D. Freedman, H. Lusic, B. D. Snyder, M. W. Grinstaff, Angew. Chem., Int. Ed. 2014, 53, 8406. [95] H. Xing, W. Bu, Q. Ren, X. Zheng, M. Li, S. Zhang, H. Qu, Z. Wang, Y. Hua, K. Zhao, L. Zhou, W. Peng, J. Shi, Biomaterials 2012, 33, 5384. [96] Y. Liu, Q. Guo, X. Zhu, W. Feng, L. Wang, L. Ma, G. Zhang, J. Zhou, F. Li, Adv. Funct. Mater. 2016, 26, 5120. [97] L. Cheng, J. Liu, X. Gu, H. Gong, X. Shi, T. Liu, C. Wang, X. Wang, G. Liu, H. Xing, W. Bu, B. Sun, Z. Liu, Adv. Mater. 2014, 26, 1886. [98] S. Zeng, H. Wang, W. Lu, Z. Yi, L. Rao, H. Liu, J. Hao, Biomaterials 2014, 35, 2934.\n[99] Z. Liu, F. Pu, S. Huang, Q. Yuan, J. Ren, X. Qu, Biomaterials 2013, 34, 1712. [100] Q. Wu, S. Liang, Q. Zhou, M. Wang, Y. Zhu, X. Yang, Int. J. Nanomed. 2015, 2325. [101] D. Ni, J. Zhang, W. Bu, C. Zhang, Z. Yao, H. Xing, J. Wang, F. Duan, Y. Liu, W. Fan, X. Feng, J. Shi, Biomaterials 2016, 76, 218. [102] Q. Yin, F. Y. Yap, L. Yin, L. Ma, Q. Zhou, L. W. Dobrucki, T. M. Fan, R. C. Gaba, J. Cheng, J. Am. Chem. Soc. 2013, 135, 13620. [103] D. Kim, Y. Y. Jeong, S. Jon, ACS Nano 2010, 4, 3689. [104] A. K. Parchur, G. Sharma, J. M. Jagtap, V. R. Gogineni,\nP. S. LaViolette, M. J. Flister, S. B. White, A. Joshi, ACS Nano 2018, 12, 6597. [105] S. Wen, K. Li, H. Cai, Q. Chen, M. Shen, Y. Huang, C. Peng, W. Hou, M. Zhu, G. Zhang, X. Shi, Biomaterials 2013, 34, 1570. [106] S. Zeng, M.-K. Tsang, C.-F. Chan, K.-L. Wong, J. Hao, Biomaterials 2012, 33, 9232. [107] H. Liu, W. Lu, H. Wang, L. Rao, Z. Yi, S. Zeng, J. Hao, Nanoscale 2013, 5, 6023. [108] Y. Liu, K. Ai, J. Liu, Q. Yuan, Y. He, L. Lu, Adv. Healthcare Mater. 2012, 1, 461. [109] Y. Liu, K. Ai, J. Liu, Q. Yuan, Y. He, L. Lu, Angew. Chem., Int. Ed. 2012, 51, 1437. [110] Z. Liu, Z. Li, J. Liu, S. Gu, Q. Yuan, J. Ren, X. Qu, Biomaterials 2012, 33, 6748. [111] Z. Yi, S. Zeng, W. Lu, H. Wang, L. Rao, H. Liu, J. Hao, ACS Appl. Mater. Interfaces 2014, 6, 3839. [112] Z. Yi, W. Lu, Y. Xu, J. Yang, L. Deng, C. Qian, T. Zeng, H. Wang, L. Rao, H. Liu, S. Zeng, Biomaterials 2014, 35, 9689. [113] R. Lv, P. Yang, F. He, S. Gai, C. Li, Y. Dai, G. Yang, J. Lin, ACS Nano 2015, 9, 1630. [114] X. Jin, F. Fang, J. Liu, C. Jiang, X. Han, Z. Song, J. Chen, G. Sun, H. Lei, L. Lu, Nanoscale 2015, 7, 15680. [115] D. Huo, J. He, H. Li, A. J. Huang, H. Y. Zhao, Y. Ding, Z. Y. Zhou, Y. Hu, Biomaterials 2014, 35, 9155. [116] A. Jakhmola, N. Anton, H. Anton, N. Messaddeq, F. Hallouard, A. Klymchenko, Y. Mely, T. F. Vandamme, Biomaterials 2014, 35, 2981. [117] L. Wen, L. Chen, S. Zheng, J. Zeng, G. Duan, Y. Wang, G. Wang, Z. Chai, Z. Li, M. Gao, Adv. Mater. 2016, 28, 5072. [118] Y. Yong, L. Zhou, Z. Gu, L. Yan, G. Tian, X. Zheng, X. Liu, X. Zhang, J. Shi, W. Cong, W. Yin, Y. Zhao, Nanoscale 2014, 6, 10394. [119] J. M. Kinsella, R. E. Jimenez, P. P. Karmali, A. M. Rush, V. R. Kotamraju, N. C. Gianneschi, E. Ruoslahti, D. Stupack, M. J. Sailor, Angew. Chem., Int. Ed. 2011, 50, 12308. [120] L. Li, Y. Lu, C. Jiang, Y. Zhu, X. Yang, X. Hu, Z. Lin, Y. Zhang, M. Peng, H. Xia, C. Mao, Adv. Funct. Mater. 2018, 28, 1704623. [121] J. Liu, X. Zheng, L. Yan, L. Zhou, G. Tian, W. Yin, L. Wang, Y. Liu, Z. Hu, Z. Gu, C. Chen, Y. Zhao, ACS Nano 2015, 9, 696. [122] L. Cheng, S. Shen, S. Shi, Y. Yi, X. Wang, G. Song, K. Yang, G. Liu, T. E. Barnhart, W. Cai, Z. Liu, Adv. Funct. Mater. 2016, 26, 2185. [123] J. Li, F. Jiang, B. Yang, X.-R. Song, Y. Liu, H.-H. Yang, D.-R. Cao, W.-R. Shi, G.-N. Chen, Sci. Rep. 2013, 3, 1998. [124] M. Branca, F. Pelletier, B. Cottin, D. Ciuculescu, C. C. Lin, R. Serra, J. G. Mattei, M. J. Casanove, R. Tan, M. Respaud, C. Amiens, Faraday Discuss. 2014, 175, 97. [125] P. J. Bonitatibus, A. S. Torres, B. Kandapallil, B. D. Lee, G. D. Goddard, R. E. Colborn, M. E. Marino, ACS Nano 2012, 6, 6650. [126] Y. Jin, Y. Li, X. Ma, Z. Zha, L. Shi, J. Tian, Z. Dai, Biomaterials 2014, 35, 5795. [127] Y. Wu, Y. Sun, X. Zhu, Q. Liu, T. Cao, J. Peng, Y. Yang, W. Feng, F. Li, Biomaterials 2014, 35, 4699. [128] M. Nikl, Meas. Sci. Technol. 2006, 17, R37. [129] M. Nikl, Phys. Status Solidi A 2000, 178, 595.\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1806381 (31 of 32)\nAdv. Mater. 2019, 1806381\n[130] C. M. Carpenter, G. Pratx, C. Sun, L. Xing, Phys. Med. Biol. 2011, 56, 3487. [131] D. Chen, S. Zhu, H. Yi, X. Zhang, D. Chen, J. Liang, J. Tian, Med. Phys. 2013, 40, 031111. [132] H. Chen, M. M. Rogalski, J. N. Anker, Phys. Chem. Chem. Phys. 2012, 14, 13469. [133] C. Zhang, K. Zhao, W. Bu, D. Ni, Y. Liu, J. Feng, J. Shi, Angew. Chem., Int. Ed. 2015, 54, 1770. [134] H. Chen, G. D. Wang, Y.-J. Chuang, Z. Zhen, X. Chen, P. Biddinger, Z. Hao, F. Liu, B. Shen, Z. Pan, J. Xie, Nano Lett. 2015, 15, 2249. [135] Y. a. Tang, J. Hu, A. H. Elmenoufy, X. Yang, ACS Appl. Mater. Interfaces 2015, 7, 12261. [136] S. Clement, W. Deng, E. Camilleri, B. C. Wilson, E. M. Goldys, Sci. Rep. 2016, 6, 19954. [137] J. P. Scaffidi, M. K. Gregas, B. Lauly, Y. Zhang, T. Vo-Dinh, ACS Nano 2011, 5, 4679. [138] L. Sudheendra, G. K. Das, C. Li, D. Stark, J. Cena, S. Cherry, I. M. Kennedy, Chem. Mater. 2014, 26, 1881. [139] T. L. Moore, F. Wang, H. Chen, S. W. Grimes, J. N. Anker, F. Alexis, Adv. Funct. Mater. 2014, 24, 5815. [140] W. Fan, W. Bu, J. Shi, Adv. Mater. 2016, 28, 3987. [141] H. Dong, S.-R. Du, X.-Y. Zheng, G.-M. Lyu, L.-D. Sun, L.-D. Li,\nP.-Z. Zhang, C. Zhang, C.-H. Yan, Chem. Rev. 2015, 115, 10725. [142] J. Zhou, Q. Liu, W. Feng, Y. Sun, F. Li, Chem. Rev. 2015, 115,\n395. [143] D. J. Naczynski, M. C. Tan, M. Zevon, B. Wall, J. Kohl, A. Kulesa,\nS. Chen, C. M. Roth, R. E. Riman, P. V. Moghe, Nat. Commun. 2013, 4, 2199. [144] G. Hong, S. Diao, J. Chang, A. L. Antaris, C. Chen, B. Zhang, S. Zhao, D. N. Atochin, P. L. Huang, K. I. Andreasson, C. J. Kuo, H. Dai, Nat. Photonics 2014, 8, 723. [145] D. J. Naczynski, C. Sun, S. Türkcan, C. Jenkins, A. L. Koh, D. Ikeda, G. Pratx, L. Xing, Nano Lett. 2015, 15, 96. [146] L. Ma, X. Zou, B. Bui, W. Chen, K. H. Song, T. Solberg, Appl. Phys. Lett. 2014, 105, 013702. [147] L. Ma, W. Chen, J. Phys. Chem. C 2011, 115, 8940. [148] L. Ma, W. Chen, Nanotechnology 2010, 21, 385604. [149] L. Song, P.-P. Li, W. Yang, X.-H. Lin, H. Liang, X.-F. Chen, G. Liu,\nJ. Li, H.-H. Yang, Adv. Funct. Mater. 2018, 28, 1707496. [150] H. Chen, X. Sun, G. D. Wang, K. Nagata, Z. Hao, A. Wang, Z. Li,\nJ. Xie, B. Shen, Mater. Horiz. 2017, 4, 1092. [151] W. Fan, B. Shen, W. Bu, F. Chen, K. Zhao, S. Zhang, L. Zhou,\nW. Peng, Q. Xiao, H. Xing, J. Liu, D. Ni, Q. He, J. Shi, J. Am. Chem. Soc. 2013, 135, 6494. [152] R. Zhang, X. Song, C. Liang, X. Yi, G. Song, Y. Chao, Y. Yang, K. Yang, L. Feng, Z. Liu, Biomaterials 2017, 138, 13. [153] L. Tian, Q. Chen, X. Yi, G. Wang, J. Chen, P. Ning, K. Yang, Z. Liu, Theranostics 2017, 7, 614. [154] W. Jiang, Q. Li, L. Xiao, J. Dou, Y. Liu, W. Yu, Y. Ma, X. Li, Y.-Z. You, Z. Tong, H. Liu, H. Liang, L. Lu, X. Xu, Y. Yao, G. Zhang, Y. Wang, J. Wang, ACS Nano 2018, 12, 5684. [155] P. Prasad, C. R. Gordijo, A. Z. Abbasi, A. Maeda, A. Ip, A. M. Rauth, R. S. DaCosta, X. Y. Wu, ACS Nano 2014, 8, 3202. [156] W. Fan, B. C. Yung, X. Chen, Angew. Chem., Int. Ed. 2018, 57, 8383. [157] C. Szabó, Nat. Rev. Drug Discovery 2007, 6, 917. [158] W. Fan, P. Huang, X. Chen, Chem. Soc. Rev. 2016, 45, 6488. [159] J. Hu, Y. a. Tang, A. H. Elmenoufy, H. Xu, Z. Cheng, X. Yang, Small 2015, 11, 5860. [160] F. Meng, H. Xu, Y. Qi, K. Xu, X. Song, S. Niu, J. Li, Chem. Res. Chin. Univ. 2012, 28, 319. [161] K. Tanabe, T. Asada, T. Ito, S.-i. Nishimoto, Bioconjugate Chem.\n2012, 23, 1909. [162] Z. Zhou, A. Chan, Z. Wang, X. Huang, G. Yu, O. Jacobson,\nS. Wang, Y. Liu, L. Shan, Y. Dai, Z. Shen, L. Lin, W. Chen, X. Chen, Angew. Chem., Int. Ed. 2018, 57, 8463.\n[163] K. Tanabe, Y. Makimura, Y. Tachi, A. Imagawa-Sato, S.-i. Nishimoto, Bioorg. Med. Chem. Lett. 2005, 15, 2321. [164] K. Tanabe, M. Sugiura, T. Ito, S.-i. Nishimoto, Bioorg. Med. Chem. 2012, 20, 5164. [165] Q. He, Biomater. Sci. 2017, 5, 2226. [166] X. Zhang, G. Tian, W. Yin, L. Wang, X. Zheng, L. Yan, J. Li, H. Su,\nC. Chen, Z. Gu, Y. Zhao, Adv. Funct. Mater. 2015, 25, 3049. [167] J. A. Bauer, Z. W. Lee, J. Zhou, C.-S. Chen, Y. Zhao, C.-H. Tan, L. Li,\nP. K. Moore, L.-W. Deng, PLoS One 2011, 6, e21077. [168] K. Kashfi, K. R. Olson, Biochem. Pharmacol. 2013, 85, 689. [169] D.-W. Zheng, B. Li, C.-X. Li, L. Xu, J.-X. Fan, Q. Lei, X.-Z. Zhang,\nAdv. Mater. 2017, 29, 1703822. [170] J. Fan, N. He, Q. He, Y. Liu, Y. Ma, X. Fu, Y. Liu, P. Huang, X. Chen,\nNanoscale 2015, 7, 20055. [171] Y. Qian, J. B. Matson, Adv. Drug Delivery Rev. 2017, 110–111,\n137. [172] H. J. Lee, D. E. Kim, D. J. Park, G. H. Choi, D.-N. Yang, J. S. Heo,\nS. C. Lee, Colloids Surf., B 2016, 146, 1. [173] Q. Song, S. Tan, X. Zhuang, Y. Guo, Y. Zhao, T. Wu, Q. Ye, L. Si,\nZ. Zhang, Mol. Pharmaceutics 2014, 11, 4118. [174] V. Kumar, S. Y. Hong, A. E. Maciag, J. E. Saavedra, D. H. Adamson,\nR. K. Prud’homme, L. K. Keefer, H. Chakrapani, Mol. Pharmaceutics 2010, 7, 291. [175] W.-P. Li, C.-H. Su, L.-C. Tsao, C.-T. Chang, Y.-P. Hsu, C.-S. Yeh, ACS Nano 2016, 10, 11027. [176] S. Yu, G. Li, R. Liu, D. Ma, W. Xue, Adv. Funct. Mater. 2018, 28, 1707440. [177] Q. He, D. O. Kiesewetter, Y. Qu, X. Fu, J. Fan, P. Huang, Y. Liu, G. Zhu, Y. Liu, Z. Qian, X. Chen, Adv. Mater. 2015, 27, 6741. [178] Z. Jin, Y. Wen, Y. Hu, W. Chen, X. Zheng, W. Guo, T. Wang, Z. Qian, B.-L. Su, Q. He, Nanoscale 2017, 9, 3637. [179] W. Fan, W. Bu, Z. Zhang, B. Shen, H. Zhang, Q. He, D. Ni, Z. Cui, K. Zhao, J. Bu, J. Du, J. Liu, J. Shi, Angew. Chem., Int. Ed. 2015, 54, 14026. [180] Z. Du, X. Zhang, Z. Guo, J. Xie, X. Dong, S. Zhu, J. Du, Z. Gu, Y. Zhao, Adv. Mater. 2018, 30, 1804046. [181] C.-K. Lim, J. Heo, S. Shin, K. Jeong, Y. H. Seo, W.-D. Jang, C. R. Park, S. Y. Park, S. Kim, I. C. Kwon, Cancer Lett. 2013, 334, 176. [182] J. F. Lovell, T. W. B. Liu, J. Chen, G. Zheng, Chem. Rev. 2010, 110, 2839. [183] Z. Zhen, W. Tang, C. Guo, H. Chen, X. Lin, G. Liu, B. Fei, X. Chen, B. Xu, J. Xie, ACS Nano 2013, 7, 6988. [184] W. Tang, Z. Zhen, M. Wang, H. Wang, Y.-J. Chuang, W. Zhang, G. D. Wang, T. Todd, T. Cowger, H. Chen, L. Liu, Z. Li, J. Xie, Adv. Funct. Mater. 2016, 26, 1757. [185] Z. Zhen, W. Tang, M. Wang, S. Zhou, H. Wang, Z. Wu, Z. Hao, Z. Li, L. Liu, J. Xie, Nano Lett. 2017, 17, 862. [186] G. Lan, K. Ni, R. Xu, K. Lu, Z. Lin, C. Chan, W. Lin, Angew. Chem., Int. Ed. 2017, 56, 12102. [187] W. Chen, J. Zhang, J. Nanosci. Nanotechnol. 2006, 6, 1159. [188] K. Cheng, M. Sano, C. H. Jenkins, G. Zhang, D. Vernekohl,\nW. Zhao, C. Wei, Y. Zhang, Z. Zhang, Y. Liu, Z. Cheng, L. Xing, ACS Nano 2018, 12, 4946. [189] A. Kamkaew, F. Chen, Y. Zhan, R. L. Majewski, W. Cai, ACS Nano 2016, 10, 3918. [190] Y. Liu, W. Chen, S. Wang, A. G. Joly, Appl. Phys. Lett. 2008, 92, 043901. [191] A. H. Elmenoufy, Y. a. Tang, J. Hu, H. Xua, X. Yang, Chem. Commun. 2015, 51, 12247. [192] X. Zou, M. Yao, L. Ma, M. Hossu, X. Han, P. Juzenas, W. Chen, Nanomedicine 2014, 9, 2339. [193] E. Abliz, J. E. Collins, H. Bell, D. B. Tata, J. X-Ray Sci. Technol. 2011, 19, 521. [194] J. Couzin-Frankel, Science 2013, 342, 1432.\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1806381 (32 of 32)\nAdv. Mater. 2019, 1806381\n[195] R. Kuai, L. J. Ochyl, K. S. Bahjat, A. Schwendeman, J. J. Moon, Nat. Mater. 2017, 16, 489. [196] M. Luo, H. Wang, Z. Wang, H. Cai, Z. Lu, Y. Li, M. Du, G. Huang, C. Wang, X. Chen, M. R. Porembka, J. Lea, A. E. Frankel, Y.-X. Fu, Z. J. Chen, J. Gao, Nat. Nanotechnol. 2017, 12, 648. [197] J. R. Brahmer, S. S. Tykodi, L. Q. M. Chow, W.-J. Hwu, S. L. Topalian, P. Hwu, C. G. Drake, L. H. Camacho, J. Kauh, K. Odunsi, H. C. Pitot, O. Hamid, S. Bhatia, R. Martins, K. Eaton, S. Chen, T. M. Salay, S. Alaparthy, J. F. Grosso, A. J. Korman, S. M. Parker, S. Agrawal, S. M. Goldberg, D. M. Pardoll, A. Gupta, J. M. Wigginton, N. Engl. J. Med. 2012, 366, 2455. [198] S. L. Topalian, F. S. Hodi, J. R. Brahmer, S. N. Gettinger, D. C. Smith, D. F. McDermott, J. D. Powderly, R. D. Carvajal, J. A. Sosman, M. B. Atkins, P. D. Leming, D. R. Spigel, S. J. Antonia, L. Horn, C. G. Drake, D. M. Pardoll, L. Chen, W. H. Sharfman, R. A. Anders, J. M. Taube, T. L. McMiller, H. Xu, A. J. Korman, M. Jure-Kunkel, S. Agrawal, D. McDonald, G. D. Kollia, A. Gupta, J. M. Wigginton, M. Sznol, N. Engl. J. Med. 2012, 366, 2443. [199] J. D. Wolchok, H. Kluger, M. K. Callahan, M. A. Postow, N. A. Rizvi, A. M. Lesokhin, N. H. Segal, C. E. Ariyan, R.-A. Gordon, K. Reed, M. M. Burke, A. Caldwell, S. A. Kronenberg, B. U. Agunwamba, X. Zhang, I. Lowy, H. D. Inzunza, W. Feely, C. E. Horak, Q. Hong, A. J. Korman, J. M. Wigginton, A. Gupta, M. Sznol, N. Engl. J. Med. 2013, 369, 122. [200] E. B. Garon, N. A. Rizvi, R. Hui, N. Leighl, A. S. Balmanoukian, J. P. Eder, A. Patnaik, C. Aggarwal, M. Gubens, L. Horn, E. Carcereny, M.-J. Ahn, E. Felip, J.-S. Lee, M. D. Hellmann, O. Hamid, J. W. Goldman, J.-C. Soria, M. Dolled-Filhart, R. Z. Rutledge, J. Zhang, J. K. Lunceford, R. Rangwala, G. M. Lubiniecki, C. Roach, K. Emancipator, L. Gandhi, N. Engl. J. Med. 2015, 372, 2018. [201] M. A. Postow, M. K. Callahan, C. A. Barker, Y. Yamada, J. Yuan, S. Kitano, Z. Mu, T. Rasalan, M. Adamow, E. Ritter, C. Sedrak, A. A. Jungbluth, R. Chua, A. S. Yang, R.-A. Roman, S. Rosner, B. Benson, J. P. Allison, A. M. Lesokhin, S. Gnjatic, J. D. Wolchok, N. Engl. J. Med. 2012, 366, 925. [202] H. E. Barker, J. T. E. Paget, A. A. Khan, K. J. Harrington, Nat. Rev. Cancer 2015, 15, 409. [203] K. Lu, C. He, N. Guo, C. Chan, K. Ni, G. Lan, H. Tang, C. Pelizzari, Y.-X. Fu, M. T. Spiotto, R. R. Weichselbaum, W. Lin, Nat. Biomed. Eng. 2018, 2, 600. [204] A. Schroeder, D. A. Heller, M. M. Winslow, J. E. Dahlman, G. W. Pratt, R. Langer, T. Jacks, D. G. Anderson, Nat. Rev. Cancer 2012, 12, 39. [205] K. Hayashi, M. Nakamura, K. Ishimura, Adv. Healthcare Mater. 2013, 2, 756. [206] A. L. Harris, Nat. Rev. Cancer 2002, 2, 38. [207] L. Harrison, K. Blackwell, Oncologist 2004, 9, 31. [208] A. M. Jubb, F. M. Buffa, A. L. Harris, J. Cell. Mol. Med. 2010, 14, 18. [209] H. Minn, T. J. Grönroos, G. Komar, O. Eskola, K. Lehtiö, J. Tuomela, M. Seppänen, O. Solin, Curr. Pharm. Des. 2008, 14, 2932. [210] E. D. Gregorio, G. Ferrauto, E. Gianolio, S. Lanzardo, C. Carrera, F. Fedeli, S. Aime, ACS Nano 2015, 9, 8239. [211] S. Carlin, J. L. Humm, J. Nucl. Med. 2012, 53, 1171. [212] Y. Li, Y. Sun, J. Li, Q. Su, W. Yuan, Y. Dai, C. Han, Q. Wang, W. Feng, F. Li, J. Am. Chem. Soc. 2015, 137, 6407. [213] I. N. Fleming, R. Manavaki, P. J. Blower, C. West, K. J. Williams, A. L. Harris, J. Domarkas, S. Lord, C. Baldry, F. J. Gilbert, Br. J. Cancer 2015, 112, 238. [214] H. Shi, Z. Wang, C. Huang, X. Gu, T. Jia, A. Zhang, Z. Wu, L. Zhu, X. Luo, X. Zhao, N. Jia, F. Miao, Small 2016, 12, 3995. [215] D. T. Ginat, R. Gupta, Annu. Rev. Biomed. Eng. 2014, 16, 431. [216] C. M. Hattinger, M. Fanelli, E. Tavanti, S. Vella, S. Ferrari, P. Picci, M. Serra, Expert Opin. Emerging Drugs 2015, 20, 495. [217] B. N. Patel, J. V. Thomas, M. E. Lockhart, L. L. Berland, D. E. Morgan, Clin. Radiol. 2013, 68, 148. [218] R. Forghani, B. D. Man, R. Gupta, Neuroimaging Clin. North Am. 2017, 27, 371. [219] Y. Jin, D. Ni, L. Gao, X. Meng, Y. Lv, F. Han, H. Zhang, Y. Liu, Z. Yao, X. Feng, W. Bu, J. Zhang, Adv. Funct. Mater. 2018, 28, 1802656. [220] H. Chen, D. C. Colvin, B. Qi, T. Moore, J. He, O. T. Mefford, F. Alexis, J. C. Gore, J. N. Anker, J. Mater. Chem. 2012, 22, 12802. [221] M. J. Pushie, I. J. Pickering, M. Korbas, M. J. Hackett, G. N. George, Chem. Rev. 2014, 114, 8499. [222] C. J. Serpell, R. N. Rutte, K. Geraki, E. Pach, M. Martincic, M. Kierkowicz, S. De Munari, K. Wals, R. Raj, B. Ballesteros, G. Tobias, D. C. Anthony, B. G. Davis, Nat. Commun. 2016, 7, 13118. [223] M. M. Gottesman, T. Fojo, S. E. Bates, Nat. Rev. Cancer 2002, 2, 48. [224] H. S. Jung, J. Han, H. Shi, S. Koo, H. Singh, H.-J. Kim, J. L. Sessler, J. Y. Lee, J.-H. Kim, J. S. Kim, J. Am. Chem. Soc. 2017, 139, 7595. [225] H. Chen, J. Tian, W. He, Z. Guo, J. Am. Chem. Soc. 2015, 137, 1539. [226] W. R. Wilson, M. P. Hay, Nat. Rev. Cancer 2011, 11, 393. [227] M. Dean, T. Fojo, S. Bates, Nat. Rev. Cancer 2005, 5, 275. [228] J. Gao, S.-S. Feng, Y. Guo, Nanomedicine 2012, 7, 465. [229] J. Shen, Q. He, Y. Gao, J. Shi, Y. Li, Nanoscale 2011, 3, 4314. [230] X. Duan, J. Xiao, Q. Yin, Z. Zhang, H. Yu, S. Mao, Y. Li, ACS Nano 2013, 7, 5858. [231] Y. Gao, Y. Chen, X. Ji, X. He, Q. Yin, Z. Zhang, J. Shi, Y. Li, ACS Nano 2011, 5, 9788. [232] L. Pan, J. Liu, Q. He, L. Wang, J. Shi, Biomaterials 2013, 34, 2719. [233] W. Fan, B. Shen, W. Bu, X. Zheng, Q. He, Z. Cui, K. Zhao, S. Zhang, J. Shi, Chem. Sci. 2015, 6, 1747. [234] L. Pan, Q. He, J. Liu, Y. Chen, M. Ma, L. Zhang, J. Shi, J. Am. Chem. Soc. 2012, 134, 5722. [235] R. Vankayala, C.-L. Kuo, K. Nuthalapati, C.-S. Chiang, K. C. Hwang, Adv. Funct. Mater. 2015, 25, 5934. [236] J. Zhao, W. Wu, J. Sun, S. Guo, Chem. Soc. Rev. 2013, 42, 5323. [237] M. C. DeRosa, R. J. Crutchley, Coord. Chem. Rev. 2002, 233–234, 351. [238] C. S. Jin, J. F. Lovel, J. Chen, G. Zheng, ACS Nano 2013, 7, 2541. [239] Z. Hou, Y. Zhang, K. Deng, Y. Chen, X. Li, X. Deng, Z. Cheng, H. Lian, C. Li, J. Lin, ACS Nano 2015, 9, 2584. [240] A. C. S. Samia, X. Chen, C. Burda, J. Am. Chem. Soc. 2003, 125, 15736. [241] H. Wang, B. Lv, Z. Tang, M. Zhang, W. Ge, Y. Liu, X. He, K. Zhao, X. Zheng, M. He, W. Bu, Nano Lett. 2018, 18, 5768."
    } ],
    "references" : [ {
      "title" : "Oncol",
      "author" : [ "A.Z. Wang", "J.E. Tepper", "J. Clin" ],
      "venue" : "2014, 32,",
      "citeRegEx" : "8",
      "shortCiteRegEx" : null,
      "year" : 2879
    }, {
      "title" : "Biochem",
      "author" : [ "T. Paunesku", "S. Vogt", "J. Maser", "B. Lai", "G. Woloschak", "J. Cell" ],
      "venue" : "2006, 99,",
      "citeRegEx" : "74",
      "shortCiteRegEx" : null,
      "year" : 1489
    }, {
      "title" : "Nanotechnol",
      "author" : [ "W. Chen", "J. Zhang", "J. Nanosci" ],
      "venue" : "2006, 6,",
      "citeRegEx" : "187",
      "shortCiteRegEx" : null,
      "year" : 1159
    }, {
      "title" : "J",
      "author" : [ "J.R. Brahmer", "S.S. Tykodi", "L.Q.M. Chow", "W.-J. Hwu", "S.L. Topalian", "P. Hwu", "C.G. Drake", "L.H. Camacho", "J. Kauh", "K. Odunsi", "H.C. Pitot", "O. Hamid", "S. Bhatia", "R. Martins", "K. Eaton", "S. Chen", "T.M. Salay", "S. Alaparthy", "J.F. Grosso", "A.J. Korman", "S.M. Parker", "S. Agrawal", "S.M. Goldberg", "D.M. Pardoll", "A. Gupta", "J.M. Wigginton", "N. Engl" ],
      "venue" : "Med. 2012, 366,",
      "citeRegEx" : "197",
      "shortCiteRegEx" : null,
      "year" : 2455
    }, {
      "title" : "J",
      "author" : [ "S.L. Topalian", "F.S. Hodi", "J.R. Brahmer", "S.N. Gettinger", "D.C. Smith", "D.F. McDermott", "J.D. Powderly", "R.D. Carvajal", "J.A. Sosman", "M.B. Atkins", "P.D. Leming", "D.R. Spigel", "S.J. Antonia", "L. Horn", "C.G. Drake", "D.M. Pardoll", "L. Chen", "W.H. Sharfman", "R.A. Anders", "J.M. Taube", "T.L. McMiller", "H. Xu", "A.J. Korman", "M. Jure-Kunkel", "S. Agrawal", "D. McDonald", "G.D. Kollia", "A. Gupta", "J.M. Wigginton", "M. Sznol", "N. Engl" ],
      "venue" : "Med. 2012, 366,",
      "citeRegEx" : "198",
      "shortCiteRegEx" : null,
      "year" : 2443
    }, {
      "title" : "J",
      "author" : [ "E.B. Garon", "N.A. Rizvi", "R. Hui", "N. Leighl", "A.S. Balmanoukian", "J.P. Eder", "A. Patnaik", "C. Aggarwal", "M. Gubens", "L. Horn", "E. Carcereny", "M.-J. Ahn", "E. Felip", "J.-S. Lee", "M.D. Hellmann", "O. Hamid", "J.W. Goldman", "J.-C. Soria", "M. Dolled-Filhart", "R.Z. Rutledge", "J. Zhang", "J.K. Lunceford", "R. Rangwala", "G.M. Lubiniecki", "C. Roach", "K. Emancipator", "L. Gandhi", "N. Engl" ],
      "venue" : "Med. 2015, 372,",
      "citeRegEx" : "200",
      "shortCiteRegEx" : null,
      "year" : 2018
    }, {
      "title" : "Med",
      "author" : [ "S. Carlin", "J.L. Humm", "J. Nucl" ],
      "venue" : "2012, 53,",
      "citeRegEx" : "211",
      "shortCiteRegEx" : null,
      "year" : 1171
    }, {
      "title" : "Chem",
      "author" : [ "H. Chen", "J. Tian", "W. He", "Z. Guo", "J. Am" ],
      "venue" : "Soc. 2015, 137,",
      "citeRegEx" : "225",
      "shortCiteRegEx" : null,
      "year" : 1539
    } ],
    "referenceMentions" : [ {
      "referenceID" : 1,
      "context" : "XEOL offers higher resolution and sensitivity than UV–vis or near-infrared (NIR) light-excited luminescence imaging methods,[74,75] thus promising enormous application potential.",
      "startOffset" : 124,
      "endOffset" : 131
    }, {
      "referenceID" : 2,
      "context" : "[158] To solve this problem, X-ray is introduced as a promising excitation source to break the restrictions of the shallow tissue penetration.[186,187] The X-ray induced PDT (X-PDT) is not only a simple PDT derivative, but a synchronous combination of PDT and RT.",
      "startOffset" : 142,
      "endOffset" : 151
    }, {
      "referenceID" : 2,
      "context" : "in 2006.[187] They attached scintillation nanoparticles with PSs such as porphyrins, bis-cyclometallated Ir(III) complexes, fullerenes, and TiO2 or ZnO semiconductor nanoparticles for in vivo PDT treatment.",
      "startOffset" : 8,
      "endOffset" : 13
    } ],
    "year" : 2019,
    "abstractText" : "Dr. W. Fan, Dr. W. Tang, Dr. J. Lau, Dr. Z. Shen, Prof. X. Chen Laboratory of Molecular Imaging and Nanomedicine National Institute of Biomedical Imaging and Bioengineering National Institutes of Health Bethesda, MD 20892, USA E-mail: wei.tang4@nih.gov; shawn.chen@nih.gov Prof. J. Xie Department of Chemistry University of Georgia Athens, GA 30602, USA Prof. J. Shi State Key Laboratory of High Performance Ceramics and Superfine Microstructures Shanghai Institute of Ceramics Chinese Academy of Sciences Shanghai 200050, P. R. China The ORCID identification number(s) for the author(s) of this article can be found under https://doi.org/10.1002/adma.201806381.",
    "creator" : "Adobe InDesign CS6 (Macintosh)"
  }
}